CA2068582A1 - Temporary stent and methods for use and manufacture - Google Patents
Temporary stent and methods for use and manufactureInfo
- Publication number
- CA2068582A1 CA2068582A1 CA002068582A CA2068582A CA2068582A1 CA 2068582 A1 CA2068582 A1 CA 2068582A1 CA 002068582 A CA002068582 A CA 002068582A CA 2068582 A CA2068582 A CA 2068582A CA 2068582 A1 CA2068582 A1 CA 2068582A1
- Authority
- CA
- Canada
- Prior art keywords
- stent
- vessel
- wires
- temporary
- braid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25F—PROCESSES FOR THE ELECTROLYTIC REMOVAL OF MATERIALS FROM OBJECTS; APPARATUS THEREFOR
- C25F3/00—Electrolytic etching or polishing
- C25F3/16—Polishing
- C25F3/22—Polishing of heavy metals
- C25F3/24—Polishing of heavy metals of iron or steel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/88—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/9517—Instruments specially adapted for placement or removal of stents or stent-grafts handle assemblies therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M29/00—Dilators with or without means for introducing media, e.g. remedies
- A61M29/02—Dilators made of swellable material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
- A61F2002/30672—Features concerning an interaction with the environment or a particular use of the prosthesis temporary
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
- A61F2002/30677—Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/0033—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements made by longitudinally pushing a protrusion into a complementary-shaped recess, e.g. held by friction fit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/005—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements using adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0059—Additional features; Implant or prostheses properties not otherwise provided for temporary
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Abstract
ABSTRACT OF THE DISCLOSURE
A temporary stent for supporting a region of a vessel in a body comprising a composite stent portion and an actuator portion and methods for the use and manufacture thereof. The composite stent portion is comprised of an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel and perfusable end portions connected to and forming ends of the vessel supporting portion and adapted to allow fluid flow therethrough. The composite stent portion is comprised of a plurality of resilient metallic wires coated with a polymeric material to provide stability for both lifting and maintaining a vessel.
A method is disclosed for deployment of the composite stent to maintain vessel patency during occurrence of an intimal flap, vasoconstriction or vasospasm.
A temporary stent for supporting a region of a vessel in a body comprising a composite stent portion and an actuator portion and methods for the use and manufacture thereof. The composite stent portion is comprised of an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel and perfusable end portions connected to and forming ends of the vessel supporting portion and adapted to allow fluid flow therethrough. The composite stent portion is comprised of a plurality of resilient metallic wires coated with a polymeric material to provide stability for both lifting and maintaining a vessel.
A method is disclosed for deployment of the composite stent to maintain vessel patency during occurrence of an intimal flap, vasoconstriction or vasospasm.
Description
` 2~68~2 BACKGROUND OF THE INV~NTION
This invention relatas to devices known as stents which provide support to a vessel, such as a blood vessel, and in particular to stents that are both temporary and removable.
Obstructive coronaxy artery disease is one of most serious health problems facing our society today.
This disease is the result of the deposit of fatty substances on the interior surface of the walls of the arteries. The build up or lesion of such deposits results in a narrowing of the diameter of the artery which restricts the blood flow through the artery.
This condition wherein the artery is narrowed is known as stenosis. The lesion may form in any part of the artery and in some instances the deposits may form at the intersectivn between two arteries, that is, where the section where the two arteries form a generally "Y"
configuration (e.g. bifurcate~ trifurcate, and so on~.
There have been significant developments of the treatment of such obstructive coronary disease in the recent past. Coronary artery~bypass graft surgery is often used to treat this disease. Bypass surgery, however, has the disadvantage that it is extremely invasive and traumatic to the patient. Some of the .. - :: : .. ~ -: :
This invention relatas to devices known as stents which provide support to a vessel, such as a blood vessel, and in particular to stents that are both temporary and removable.
Obstructive coronaxy artery disease is one of most serious health problems facing our society today.
This disease is the result of the deposit of fatty substances on the interior surface of the walls of the arteries. The build up or lesion of such deposits results in a narrowing of the diameter of the artery which restricts the blood flow through the artery.
This condition wherein the artery is narrowed is known as stenosis. The lesion may form in any part of the artery and in some instances the deposits may form at the intersectivn between two arteries, that is, where the section where the two arteries form a generally "Y"
configuration (e.g. bifurcate~ trifurcate, and so on~.
There have been significant developments of the treatment of such obstructive coronary disease in the recent past. Coronary artery~bypass graft surgery is often used to treat this disease. Bypass surgery, however, has the disadvantage that it is extremely invasive and traumatic to the patient. Some of the .. - :: : .. ~ -: :
2~8~82 recent developments provide a less invasive and less traumatic alternative to bypasæ surgery. Two o~ khese recent developments are known as anyioplasty and atherectomy procedures.
Angioplasty is a procedure in which a balloon is positioned on the inside of the artery at the site of the lesion and expanded in order to compress the materials at the lesion and thus open the restricted area in the artery. In this procedure, an elastic balloon is attached to one end of a small diameter flexible catheter which includes means for inflating the balloon from the other end of the catheter. The catheter is maneuvered through the patient's vessels to the site of the lesion with the balloon in uninflated form. When the uninflated balloon is properly positioned at the lesion, the balloon is then inflated to dilatate the restricted area.
Atherectomy is a procedure in which a small cutting tool is attached to the end of a small diameter flexible catheter and maneuvered through the patient's arterial system to the site of the lesion in the diseased artery. When the cutting tool is properly positioned, the tool is used to cut and remove the deposits from the surface of the diseased artery.
Although these two procedures provida less traumatic alternatives to bypass surgery, they are not without risk. It is possible that following procedures such as angioplasty or atherectomy the artery or blood vessel may collapse or be susceptihle to constriction.
In some instances it may also be necessary to abort or "bail out" procedures such as angioplasty or atherectomy due to some type of unexpected complication.
:
`~ 20~82 In these situations it is necessary to maintain the integrity of the region of the artery until the artery is repaired or stabilizes. That is, following some angioplasty or atherectomy procedures or in a "bail-out" situation, it may be necessary to provide support to a artery or blood vessel on a temporary basis while there is an immediate risk that the region may collapse. This support must be provided until the region is repaired or stabilized. To provide this support, a device known as a stent may be installed at the desired region. A stent is a device which is used to hold or maintain the diameter of the artery or vessel.
Although some stents are available in the art, these are generally of the type intended for permanent use. This type of permanent stent is implanted in a patient's vascular system and remains in -place after the procedure or operation. Such permanent types of stents are shown, for example, in U.S. Patent Nos. 4,913,141, 4,878,906, 4,856,516 and 4,820,298.
These permanent type of stents may not always be desir~d for the situations described above. First, it may be unnecessary and even undesirable to install a permanent device when only temporary support is needed.
Further, these permanent type of stents may require a relatively complicated procedure to install. Further, use of permanent stents results in extended hospital o~servation and recovery time. Additionally, a complement of drug therapies are required in order to offset the bioreaction resulting in thrombus formation or smooth muscle cell proliferation on the stent surface. These drug therapies may be required for a significant period of time until new normal endothelial :: : .: .: . ;.- : , . .: . : .. : : - :: : . . : :: :
20~8582 cells have ~ormed. In situations such as a "bail-out it is desirable for the physician to have the ability to quickly maneuver the stent to the desired location and quickly and easily place the stent in its operating mode.
A temporary stent on the other hand may be particularly useful in situations where it is intended to be used in the patient only for several minutes or days and then removed. For example, use of a temporary stent in a bail-out situation will enable the physician to defer a more complicated procedure until a patient's condition is more stable, or in some cases eliminate further procedures by resecuring the vessel geometry which allows near normal blood flow.
A temporary stent may have particular usefulness in situations such as when an intimal flap is encountered or during occurrrences of vasoconstriction or vasospasm or in situations in which there is a potential for such conditions to occur such as following angioplasty. An intimal flap occurs when a portion of the vessel wall partially or completely tears off and hangs down into the blood flow path. An intimal flap may occur during or after an angioplasty procedure. If the flap is large, it may entirely occlude the vessel lumen. The flap may heal itself if it can be maintained in place against the vessel from which it tore.
Vasoconstriction or vasospasm also may occur during or after angioplasty. Vasoconstriction or vasospasm in many cases may accompany the occurrence of an intimal flap, but in many other cases, vasoconstriction or vasospasm may occur independent of an intimal flap. During vasoconstriction or vasospasm, muscles around th~ vessel contract and can partially or completPly occlude the vessel. If the vessel can be maintained open, vasoconstriction or vasospasm may cease after a period of time. Medicines may be administered to treat the vasoconstriction or vasospasm. Whereas a small force may be sufficient to maintain an intimal flap against the vessel wall and maintain blood flow, a significantly greater force would usually be needed to keep a vessel open during an episode of vasoconstriction or vasospasm.
It is essential that a temporary stent be relatively easy to both install and remove. Since the temporary stent remains in place for a period of time, it is important that the temporary stent not block the flow of blood through the vessel. That is, the blood must be able to travel through the vessel in which the temporary stent is installed while the stent is in place. Further, since the lesions often occur at the intersection of two vessels, in order to position the temporary stent it is may be necessary to place the stent across the intersection. Therefore, it is critical that the stent provide a flow path radially as well as axially or longitudinally. This arrangement will allow blood flow to both of the intersecting arteries.
It is also desirable to have the ability to deliver medicines to the vessel either upstream or downstream of temporary stent while the stent is in place.
Since th~ temporary stent will be removed after a period of time, it is important that the temporary stent not permanently adhere to the inner walls of the vessel in which it is placed. In addition, a temporary stent should have no tendency, or only a minimal tendency, to cause clotting.
Accordingly, it is an object of the present invention to provide a stent that may be placed temporarily in a patient's vascular system and which is readily rPmovable.
SUMMARY OF THE INVENTION
The present invention relates to a temporary stent for supporting a region of a vessel in a body comprising a composite portion and an actuator portion and methods for the use and manufacture thereof. The composite stent portion is comprised of an elongate perfusable vessel supportiny portion adapted to be configurable between a reduced si2e for plac~ment in the vessel and removal therefrom and an expanded size for structurally supporting the vessel. The composite stent portion is comprised of a plurality of resilient metallic wires coated with a polymeric material to provide stability for both lifting and maintaining a vessel.
With this arrangement, the temporary stent may be positioned in the desired region and may be used to maintain vessel patency during the occurrence of an intimal flapl vasoconstriction, vasospasm, or other conditions that occlude the vessel lumen or when there is a potential that such conditions may occur such as following angioplasty.
BRIEF DESCRIPTION OF THE FIGURES `
Figure 1 depicts a first embodiment of the present invention.
~' . ; . ................. :
. ,. . , ~ ;
.
~068~2 Figure 2 shows a distal portion o~ the embodiment depicted in Figure 1 with the stent portion in a reduced contracted configuration.
Figure 3 shows a distal portion of the embodiment depicted in Figure 1 with the stent portion in an expanded configuration.
Figure 4 is a longitudinal sectional view showing a portion of the embodiment depicted in Figure 1.
Figure 5 is a longitudinal sectional view showing a portion of the embodiment depicted in Figure 1.
Figure 6 depicts a distal portion of another embodiment of the present invention.
Figure 7 depicts a distal portion of another embodiment of the present invention in a contracted configuration.
Figure 8 depicts the distal portion of the embodiment shown in Figure 7 in an expanded configuration.
Figure 9 depicts another embodiment of the present invention.
Figure 10 is a cross section of an embodiment of a wire component along lines 10-10' of Figure 2.
Figure 11 is a lvngitudinal sectional view of a distal portion of another embodiment of the present invention.
Figure 12 is a cross section of a proximal portion of an embodiment of the present invention showing aspects of an embodiment of the manifold actuator assembly.
Figure 13 is a perspective view of a portion of th~ manifold actuator assembly of Figure 12.
2~8~2 DETAILED DESCRIPTION OF THE
PRESENTLY PREFERRED EMBODIMENTS
Ref~rring to Figure 1, there is depicted a first embodiment of ~he present invention. The embodiment of Figure 1 is a temporary stent 10 which can be placed in the vascular system of a patient after a procedure such as angioplasty, atherectomy or other interventional therapies. Although the temporary stent 10 is particularly useful in procedures involving blood lo vessels, it may be used in other fluid carrying vessels in the patient's body. As used herein, the term "vascular system" refers to a vessel for conveying body fluids. The temporary stent 10 is intended for placement in a vascular system for limited durations of time from several minutes to up to several days.
In the embodiment of the invention depicted in Figure 1, the temporary stent 10 includes a perfusable stent portion 14 and an actuator portion 18.
The stent portion 14 is connected to a distal end 20 of the actuator portion 18. When the temporary stent 10 is being used in a patient, the actuator portion ~8 extends proximally from its connection to the stent portion 14 through the vascular system and out of the body of the patient. In one embodiment, the proximal end 22 of the actuator portion 18 extends out the body of the patient is connected to one or more, ror example two, manifolds 24 and 26.
The stent portion 14 is expandable and contractable so that it can be positioned in the vascular system at the specific location where needed and then expanded to an appropriate size (i.~.
approximately the same diameter as the vessel in the region where placed) thus supporting that vascular .
:- : -, . ::, , , ~ 2068~82 g region. When in its expanded configura~ion, the ~ten~
portion 14 provides support to the vascular walls thereby preventing constriction of the vascular region in which it i5 located and maintaining the vascular lumen open.
The construction and materials for the stent portion 1~ should provide that the stent be perfusable, i.e. it should allow blood flow therethrough both in the axial direction of the vessel to maintain blood flow through the region in which the stent is located as well as in the radial direction so that any vessels that branch off from the region of the vessel into which the stent portion is placed will not be occluded.
Thus, the stent portion 14 should be relatively transparent to blood flow in order to maintain vascular function while at the same time providing support for the vessel walls in the region where it is located.
Expansion and contraction of the stent portion 14 inside the patient's body may be accomplished from outside of the patient's body by means of manipulation of the actuator portion 18 from the proximal end 22 thereof which is located outside the patient's body. In this embodiment, the actuator portion 18 comprises a first elongate member 28 that connects to a proximal end 30 of the stent portion 14 and a second elongate member 32 that connects to the distal end 34 of the stent portion 14. Relative movement of the first elongate member 28 and the second elongate member 32 causes expansion and contraction of the stent portion 14, as explained in more detail below. The distaI end 20 of the actuator portion ~8 remains in place in the body during the period of time that the stent portion 14 is in place in the vascular _ 9 _ . . ~ , .
. . v ~a~s2 system and during this time the proximal end 22 oP the actuator portion 18 extends out of the patient's body.
At the proximal end of the actuator portion 1~, the first elongate member 28 terminates at a manifold 24 and the second elongate member 32 terminates at the manifold 26. In one embodiment, these manifolds include hemostatic valves and Y-connecters for administering fluids, such as medicines through these manifolds, as described below.
In a preferred embodiment, the stent portion 14 is comprised of a braid made of a plurality of helically wound wires forming an elongated hollow tube.
Typically, half of the wires forming this tube will be wound in one helical direction and the other half will be wound in the opposite helical direction and interwoven with the first half. Braiding of these wires provides for an elongated, expandable hollow tube that can, in a preferred embodiment, increase in diameter when the ends of the hollow tube are moved closer relative to each other and decrease in diameter when the ends of the hollow tube are move apart relative to each other. The ratio by which the stent portion expands depends upon the spacing betwPen adjacent wires that make up the braid as well as the cross sectional dimensions of each of the individual wires.
The stent portion 14 may be provided in a wide range of sizes and stiffnesses to meet the requirements for use with different lesions, flaps, or vasoconstrictions in a patient's vascular system. The stent portion 14 is constructed to be flexible enough to traverse its way to the region of the vascular system where it is to be located and expanded to 2~8~82 : `
provide support for the region of ~he vascular system, such as the site of previous angioplasty or other treatment.
The stent portion 14 terminates in a distal end 34. Located inside the hollow tube of the stent portion 14 is the second (or inner) elongate member 32.
The second elongate member 32 is connected to the distal end 34 of the stent portion 14, as explained below. The second elongate member 32 extends lo proximally from its connection to the distal end 34 of the stent portion 14, through the hollow tube of the stent portion 14, and through an inner lumen of the first elongate member 28 to the proximal end thereof.
In accordance with this embodiment, relative movement between the first elongate member 28 and the second elongate member 32 causes corresponding movement of the proximal end 30 and distal end 34 of the stent portion 14 thus in turn causing expansion or contraction of the diameter of the elongate hollow tube of the stent portion 14.
In Figure 2, the temporary stent 10 is depicted in its constricted ronfiguration with the elongate hollow tube of the stent portion 14 having a reduced diameter. In this configuration, the second elongate member 32 extends distally from the first elongate member 28 so that the length of the stent portion 14 is L1. In Figure 3, the second elongate member 32 is positioned at a location more proximate relative to the first elongate member 28 than in Figure 2 (i~e., in the direction of arrow 35) causing the length of the stent portion 14 to be equal to L2 ~L2 being less than Ll). In the process of moving proximally r~lative to the first elongate member 28, , .- : - , ,.,~ ., : , :
2~6~582 the second elongate member 32 causes the proximal and distal ends 30 and 34, respectively, of the stent portion 14 to move relatively closer together thus causing the diameter of the elongate hollow tube of the stent portion 14 to expand to a dimension suitable for supporting a region of the vascular system. The temporary stent 10 can be maintained in this expanded configuration by fixing the proximal ends of the first and second elongate members 28 and 32 for the duration of the time that the temporary stent 10 is maintained in the vascular system. This may be done by attaching a clamp 39 or similar device to the proximal ends of the first elongate member 28 and the second elongate member 32 at the manifolds 24 and 26. These two elongate members can be later disengaged from each other to permit reducing the diameter of the temporary stent 10 for removal thereof from the body. In alternative embodiments, the first and second elongate mem~ers may be fixed by means of an actuator manifold, as described below.
In order to provide a means by which the position of the temporary stent 10 in the body of the patient can be determined, one or more radiopaque markers, e.g. 40 and 41 may be located on a distal region of the stent, for example on a distal region of the second elongate member 32O These markers may be bands of radiopaque materials such as platinum, tantalum, gold, tungsten or a tungsten-iridium alloy.
Referring to Figure 11, there is illustrated a distal portion of a most preferred embodiment 200 for incorporating radiopaque markers for use in an embodiment of the temporary stent. In this embodiment, there are three radiopaque markers associated with the 20685~2 distal portion of the temporary stent. A first marker 202 is located at or adjacent to a distal end of the stent portion 14. A second marker ~04 is located at or adjacent to a proximal end of the stent portion 14. By means of these two markers 202 and 204, the length of the stent portion 14 can be determined during expansion and contrackion. A third marker 206 is fixed to the second elongate member 32 in the region corresponding to the stent portion 14. Accordingly, by observing the position of the third marker 206 relative to the first and second markers 20~ and 204, it is possible to obtain continuous feedback of the stent deployment during expansion and contraction. In a preferred embodiment, the third marker 206 is approximately adjacent to the second marker 204 when the stent portion is fully expanded and is approximately just proximal of the midline of the stent portion 14 when the stent portion 14 i5 contracted. In the preferred embodiment, the markers are made of platinum with 10%
iridium.
In a most preferred embodiment, the markers are formed of wire that is wound around the proximal and distal ends of the braid and also serve the funrtion of securing the proximal end of the braid to the first elongate member 28 and the distal end of the braid to the second elongate member 32. In the preferred embodiment, the braid is pulled down on a mandrel and the marker wire is coil wound around the ends of the braid. Then, the coils are clipped and brazed. In this manner, the braid is both secured to the catheters elongate member and markers are provided.
Instead of brazing, the markers may be secured to the elongate members by means of welding, soldering, 2~S82 adhesives, or other means. The third marker, i.e. the marker located on the inner catheter 54, may be installed similarly except that it will not be connected to the braid.
Re~erring to Figure 4, there is depicted a longitudinal cross section of the distal end of the se~ond elongate member 32. In this embodiment, the second elongate member 32 is an inner catheter 44. As depicted in Figure 2, the distal end 34 of the stent portion 14 surrounds an outside wall of the inner catheter 44. A collar 46 surrounds and affixes the distal ends of the wires that make up ths braid of the stent portion 14 to the distal end Qf the inner catheter 44 (i.e. first elongate member 32). The collar 46 may be made of a balloon tubing polyolefin or other ultra-thin wall polymers. The collar 46 may be heated to fuse to the outer wall of the inner catheter 44 or connected thereto by an adhesive or other suitable means. In this manner, the distal end 34 of the stent portion 14 may be securely fixed to the inner catheter 44 suitably for the duration of the use of the temporary stent lo. A distal tip 48 of the temporary stent 10 is formed of an extension of the inner catheter 44 distally past the collar 46. This 2 extension may be approximately 0.25 cm. This distal end may have an outer diameter of approximately 0.039 inches. The inner catheter 44 has a lumen 50 therewithin that communicatPs with an opening 52 at the distal tip 48.
Referring to Figure 5, there is a longitudinal ~ectional view depicting a portion o~ the proximal end 30 of the stent portion 14 and the actuator portion 18 and specifically the connection of . .
, :; , , , ~: : , ~ :
2~6~82 the proximal end 30 of the stent portion 14 to the first elongate member 28 of the actuator portion 18.
In this embodiment, the ~irst elongate member 28 is an outer catheter 54. As shown in Figure 5, the outer catheter 54 includes an inner tubular layer 56 and an outer tubular layer 58 that is concentric with the inner tubular layer 56. The outer diameter of the outer catheter 54 would be approximately close to, but may be slightly larger than, the contracted diameter of the stent portion 14. Thus, for coronary appli~ations, the outer catheter 54 may have an outer diameter of approximately 0.039 inches, and for peripheral applications the outer catheter 54 may have a diameter of approximately 2.10 mm. The length of the outer catheter 54 could be made to various sizes to be suitahle for different treatment sites. For coronary applications, the length of the outer catheter 54 would be approximately 175 cm, for example.
In this embodiment, the proximal end 30 of the stent portion 14 is secured between the inner and outer concentric tubular layers 56 and 58 by extending the wires of the braid proximally between these concentric layers. The concentric tubular layers 56 and 58 and the wires of the braid of the stent portion 14 may be bonded together by an appropriate adhesive or by heating. A frictional fit may also be suitable.
Preferably, the wires of the braid terminate proximally at the proximal end of the first elongate member 28.
Alternatively, the wires of the braid may extend the sntire length proximally to the proximal end of the first elongate member 28 or the wires of the braid of the stent portion 14 may extend only a short distance - 2 ~ 8 2 or an intermediate distance proximally between the concentric tubular layers 56 and 58.
In this embodiment, the inner tubular layer 56 terminates a distance proximally from the distal end of the outer tubular layer 58. This enables the outer catheter 54 (i.e., first elongate member 18) to be reduced in diameter in the distal region thereof forming a necked down portion S0 to facilitate positioning the temporary stent 10 in a region of the vascular system. The necked down portion 60 of the outer catheter 54 may be approximately 3 to 30 cm in length.
Referring again to Figure 3, when the stent portion is in its expanded configuration, the proximal 30 and distal 34 ends of the stent portion 14 will assume a proximal and distal truncated conical profile regions 62 and 64. These truncated conical profile regions 62 and 64 taper from a narro~ dimension where the wire braid is affixed to the actuator portion 18 proximally and distally (i.e., first and second elongate members 28 and 32) up to the expanded diameter of the stent portion 14. These regions 62 and 64 may be linearly tapered, but a non-linear taper may also be provided. The type of taper depends upon the type of braiding method used. Because the diameter of the second elongate member 32 is less than the diameter of the first elongate member 18, thP distal tapered region 64 may not correspond exactly in size or slope to the proximal tapered region 62. In both the proximal tapered region 62 and the distal tapered region 64, the braiding method used preferably provides for relatively large distances between adjacent wires to provide correspondingly large openings around and through the - . ,. ~
2~6~$2 plurality of wires at the ends of the stent portion 14 to facilitate blood flow therethrough.
In this embodiment, the temporary stent 10 may be positioned in the vascular region over a guidewire 70 through the lumen 50 of the inner catheter 44. The guidewire 70 may be a standard guidewire suitable for the region of the vascular ~ystem into which the stent will be located. According to this embodiment, the guidewire 70 is positioned in the vascular system across the region where it is desired to install the temporary stent 10. The guidewire 70 may be positioned by standard procedures. The diameter of the lumen 50 of the inner catheter 44 is of a sufficient size to allow the stent portion 14 to be advanced in the vascular system over the guidewire 70.
The temporary stent 10 including the sten~ portion 14 and the distal end of the actuator portion 18 is advanced over the guidewire 70. The lumen 50 of the inner catheter may be compatible with 0.014, 0.016, or 0.018 guidewires for coronary applications and with up to 0.038 guidewires for peripheral applications.
Alternatively, the temporary stent 10 could be located in the vascular region by guidin~ it through a separate catheter (e.g. a delivery catheter) large enough to contain the temporary stent 10 in its contracted configuration.
For coronary applications, the stent portion 14 of this em~odiment is expandable from a siza of approximately 1.25 mm or less to up to approximately 4.0 mm. When used for peripheral applications, the stent portion 14 of the temporary stent 10 may have a contracted diameter of less than approximately 2.0 mm and an Qxpanded diameter of up to approximately 6.0 mmO
~ 17 -:- , , :, . .: ~ : . : :
2~6~82 The length of the stent portion 14 is approximately 2.5 to 5 cm when in its most extended position (i.e. when the diameter of the stent portion 14 is in its contracted configuration). When the diameter of the stent portion is in its expanded configuration~ the length of the stent portion is somewhat less, e.g.
approximately 1.5 to 3.5 cm.
In a most preferred ~mbodiment, the stent portion is provided in two alternative lengths: 25 and 40 mm. These dimensions refer to the length of the stent portion when it is deployed to support a portion of a vessel, i.e. in the expanded configuration.
In this embodiment, fluids such as medicines may be introduced to the vascular system via the lumen 50 of the inner catheter 44 as well as through a lumen 72 of the outer catheter 54 around the inner catheter 44. Medicines introduced via the inner catheter 44 will enter the vascular system at the distal end 48 of the stent portion 14 via opening 52. In this embodiment, sufficient space is provided in the lumen 72 of the outer catheter 54 around the inner catheter 44, so that a second passageway for the introduction of fluids such as medicines to the vascular system is also provided. Medicines introduced via the lumen 72 of the outer catheter 54 will enter the vascular system at the proximal end 30 of the stent portion 14. In this manner, the attending physician has the choice of selecting the point of entry for medicines administered e.g., either upstream or downstream of the stent portion 14. For instance, medicines, such as non-thrombogenic drugs, can be administered upstream of~the stent portion 14 where they would be most effective in the region of the stent portion 14.
, , - - : ::: , . -,: ~
- . . ~ - , .~ : . . :
, ~ , :- :
~6~8~
To remove the temporary stent 10, the stent portion 14 is first contracted from its expanded configuration to a reduced configuration. To do this, the first elongate member 28 is moved proximally relative to the second elongate member 32 thereby drawing down the diameter of the stent portion 14 to a size to facilit~te removal from the vascular system.
The wires of the stent portion 14 should smoothly peel from the vessel wall causing no or only minimal trauma.
It is nvt necessary that the stent portion 14 be drawn down entirely to its completely reduced size. It is sufficient that the stent portion 14 is drawn down sufficiently to disengage the inner walls of the -vascular region and to be of a size sufficiently small to traverse the vascular system out of the body. Then, after the stent portion 14 is in a reduced configuration it may be removed from the vascular system by drawing it out by means of the attarhed actuator portion 18.
The inner catheter 44 of the elongate member 14 has a geometry and is comprised of a material to provide ~or ~lexibility, tracking, axial compressive and tensile strength and rigidity for actuation of the stent portion 14. In a most preferred embodiment, the inner catheter 44 of the elongate member 14 is comprised o~ a thin~walled polyimide. Alternatively, the inner catheter 44 may be a polycarbonate, polyester or PET (high modulus polymer~ tube. Such materials provide for the desired pxoperties.
A lubricious coating may be utilized on the inner catheter 44. The lubricious coating may be a hydrophilic material, paralyene, teflon, or silicone.
Such a coating may be utilized on either the inner or .. ~ - .
, ~ :
the outer surfaces of the inner catheter 44 or both. A
lubri~ious coating on the inner surface of the inner catheter 44 facilitates over-the-wire movement of the temporary stent. A lubricious coating on the outer surface of the inner catheter 44 provides for low friction with the outer catheter 54 for good deployment and actuation of the stent portion 14.
The outer cathPter 54 of the Plongate member 14 should also have a geometry and should be comprised of a material to provide for flexibility, tracking, axial compressive and tensile strength and rigidity for actuation of the stent portion 14. In a most preferred embodiment, the outer catheter is made of polycarbonate. Alternatively, the outer catheter may be comprised of a thin-walled polyimide, polyester or PET (high modulus polymer) tubeO
A lubricious coating may also be utilized on the outer catheter 54. The lubricious coating may be a hydrophilic material, paralyene, teflon, or silicone.
such a coating may be utilized on either the inner or the outer surfaces of the outer catheter 54 or both. A
lubricious coating on the inner surface of the outer catheter 54 provides for low friction with the inner catheter 44 for good deployment and actuation of the stent portion~l4. A lubricious coating on the outer surface of the outer catheter 5~ facilitates positioning of the temporary stent in th~ patient's vascular system.
In an alternative embodiment of the present invention, the inner catheter 44 is comprised of a .021 X .028 inch polymeric tubing. The tubing used may be a blended Poly-Ethylene comprised of High Density Polyethylene (HDPE) and Low Density Poly-Ethylene 2~6~82 (LDPE). Alternatively, the inner cathet~r 44 may also be constructed of Poly-Propylene, ~PFE te~lon or TPX.
(TPX is a trade name for the Methyl Methylpentene Copolymer manufactured by Mitsui Plastics, Inc. and distributed from White Plains, NY). The use of TPX
enables the stent to be used for ultrasound imaging of the vessel that is being supported by the stent bacause the acoustical properties of this polymer match to that of water and blood.
lo Referring to the first elongate member 28, the inner tubular layer 56 may be constructed of the same combination of polymers described for the inner catheter 44. The inner tubular layer 56 may terminate 3 to 30 cm proximally from the proximal end 30 of the stent portion 14. This provides for the ability to reduce the section of the outer layer 58 by way of a drawing lor necking operation) on the outer layer 58.
The size for this inner tubular layer 56 of the first elongate member 28 is .033 X .039 inch.
The outer tubular layer 58 of the first elongate member 28 may also be constructed of blended HDPE-LDPE, or polypropylene. The dimensions of the outer tubular layer 58 of the embodiment may be .045 X
.053 inches in the proximal section of the first elongate member 28 extending from the manifold 24 at the proximal end to approximately 3 to 30 cm from the proximal portion 30 of the stent portion 14. From this point distally, the outer tubular layer 58 may be reduced to .039 X .045. This may be accomplished by a necking or drawing operation which is achieved by pulling th~ tube through a heated die and allowing the plastic to reflow.
: : ~ ' ' , ~ ', ' 2~8~82 The inner dimension o~ the outer tubular layer 58 as well as the distal necked region 60 i~
adjusted accordingly for a 3.0 or 3.5 mm stent as may be seen to accommodate the wire of greater thickness.
Since the outer diameter of the inner tubular layer 58 is .039 inches the placement of the braid on top of this layer, i.e. in the lumen 72, adds a factor of four times the wire thickness to the profile of the device prior to installation of the outer tubular layer 58.
It is thereEore apparent that the inner diameter of the outer tubular layer 58 should be adjusted to a minimum of .047 inches for the 3~0 mm and 3.5 mm versions. The tubing dimension may then be adjusted ~or the outer tubular layer to .055.
The stent portion 14 is comprised of a composite system that provides a consistent geometry during repeated expansions and contractions. In a most pref~rred embodiment, the stent portion has a geometry comprised of a uniform cylindrical middle portion with abrupt cone shaped geometries at the distal and proximal ends. This geometry minimizes constriction or impedance of the blood flow. The cone shaped regions at the distal and proximal ends have minimal lengths and preferably form an angle from the axial direction greater than 45 degrees. In a most preferred embodiment, the length of the stent portion is appxoximately 25 mm when in the expanded configuration.
In a most preferred embodiment, the stent portion is formed of a composite braid. The composite braid i~ formed of a resilient metal alloy wire coated with a polymeric coating. In the most preferred embodiment, the wire used for the composite braid is a heat treatable cobalt-chromium-nickel-molybdenum basQd alloy, such as Elgiloy or MP35N. In a most preerred embodiment, the Elgiloy wire used in the construction of the stent portion 14 is a round wire having a diameter of approximately 0.002 to 0.0025 inches. In one embodiment, the Elgiloy wire is treated to cause a metallurgical phase change so that the wire assumes a set shape to which it will have a tendency to resiliently resume. With Elgiloy wire, this phase change may be obtained by methods that are well known in the art and include steps o~ cold working and then heat treating the wire in the desired configuration to approximately 900 to 1000 degrees Fahrenheit. Other heat treatable alloys such as a stress relieved stainless steel could he utilized. Wire of other dimensions may also be used. Preferably, the Elgiloy wire is formed into a braid of a size corresponding to the radially expanded size. Then, the wire is heat treated with the braid of the stent portion in the expanded configuration thereby imparting the desired memory shape to the braid. Th n, the braid may be drawn down to a reduced size for positioning in the vascular system. In alternative embodiments, the diameter of the stant portion in its expanded configuration may be 2~5, 3.0, 3.5, 4.0 mm or other dimensions as desired. This heat treatment imparts high resiliency and a geometrical shape memory to the wire forming the braided composite stent portion.
In further embodiments, the braid may be treated in the reduced sixe or in an intermediate size between the reduced and expanded size. In such further embodiments, the stent will tend to resume the size in which it was treated. These alternative embodiments may be preferred in certain circumstances.
- . . ~ . , : :. : , . . .
20~8~8~
The pick count of the braid i5 a faator in the amount o~ treatment and the distance o~ axial travel associated with the braided wire that ~orms the stent portion. ~The pick count is the number of crossings down a single axial line of elements per inch . For purposes of this specification, the pick count may be determined at the braiding stage before the stent is traated, such as by heating). A smaller pick count provides for less travel which which in turn minimizes trauma to the vessel. In a preferred embodiment, a braid having a pick count of less than 16 is used. In a most preferred embodiment, a braid having a pick count of 12 is used.
In a most preferred embodiment, the braid of wires that comprise the stent portion is formed of fewer than 20 wire elements. In a preferred embodiment, the stent portion is formed of 8 wire elements. At the crossing locations of the wires, the wires preferably form an axially-directed angle of 90 degrees or less and more preferably form an acute, axially-dir cted angle. This provides the advantage of minimizing the amount of material used in the stent thereby enhancing perfusion therethrough.
As mentioned above, in a most preferred embodiment, the composite stent includes a coating on the wire braid that forms the stent portion. The coating material is preferably a polymeric material such as polyurethane, silicone, or other high modulus, high elongation polymers. In a most preferred embodiment, the coating is an aliphatic polyurethane.
The coating encapsulates and adheres to the crossing points and individual wire elements that form the braid, thus alIowing rotation of these crossing points : . ~ , : , : : . ~
20~8~82 ~ 25 -through elongation of the polymer, but preventing translation of the crossing points by adherences to the wire stands. The coating is prePerably applied after the braid has been appropriately treated in an expanded configuration to impart a resiliency and memory to the metal braid, as described above. The coating thereby further enhances the memory shape characteristics. The coating may be sprayed on or applied by other methods such as by dipping or by dispersion. In a preferred embodiment, the coating is approximately less than 0.002 inches in thichness and preferably less than 0.001 inches in thickness. The coating may be thicker in some areas such as proximate to wire crossings. In alternative embodiments, other means may be utilized to "tie together" wire crossovers to enhance braid integrity as well as to impart stabilized lifting and holding properties to the braid.
In the most preferred embodiment, the stent portion possesses both dynamic and static stability.
Dynamic stability allows the stent portion to lift an intimal vessel flap or vasoconstriction. Static stability allows the stent portion to maintain the vessel lumen by holding up a flap constriction or a vasoconstriction or vasospasm once the stent portion is in its expanded configuration. With the composite stent portion comprised of Elgiloy wire coated with an aliphatic urethane, these properties are provided with relatively few wire elements thereby allowing for a high level of blood perfusion through the stent. Also, ~0 with the composite stent, the overall dimensions of the stent can be minimizPd thereby facilitating tracking of the stent device to the desired vessel location.
Through the use of the composite stent with the wir~
. ~ .
2~8~82 braid of expanded geometry memory and the non-translatable wire crossings, the number of wires need to form the stent portion can be minimized while still provi~ing the necessary stability to the stent to maintain vessel patency for extended periods of time.
With a composite stent of the materials as described above, the stent can "lift" up to three 120 gram forces applied radially to a portion of the stent at 120 degree intervals around the location. A stent a~cording to this embodiment would therefore provide - for the ability to maintain the vessel open during most occurrences of vasoconstriction or vasospasm.
When devices are designed for use within the coronary arterial system size becomes a very significant factor. Each 1/lOOOth of an inch is significant both because of the primary concern which is restriction of flow, but also because of the added stiffness that results when a composite of tubular layers are sandwiched together to form the actuator member. For this reason, in one alternative embodiment, wire of rectangular cross section (herein referred to as flat wire) are utilized. One size of wire to make a 2.0 mm stent is .003 inches. For a 2.5 mm stent, wire of a size of .003 to ~0035 may be used.
For a 3.0 and 3.5 mm stent, wire of either .0035 or .0040 should ke used. From this, the advantage of using flat wire beGomes apparent. For each of the stent sizes, added thickness due to the braid is detailad below.
SIZE WIRE SIZE DIAMETRAL
2 . O . 0015 FhAT . 006 2 . 0 . 003 ROUND . 012 20~8~82 2.5 .0015 FhAT ~006 2.5 .003 ROUND .01 .0035 ROUND .014 3.0 ~002 FhAT .008 3.0 .0035 ROUND .014 .004 ROUND .016 3.5 .002 FLAT .008 3.5 .0035 ROUND .012 .004 ROUND .016 From the abovel the significance of the use of flat wire can be appreciated. It may be ssen that a large profile change results using flat wire as opposed to round wire. Additionally, the use of the larger flat wire results in devices that are considerably stiffer.
In this alternative embodiment, the braiding operation uses flat wire. In this embodiment, a 2.0 mm stent is constructed with a braid mesh network using stainless steel wire of rectangular cross section with a thickness of .001 inch X .004 inch. In this embodiment, for a 2.5 mm stent the wire used is stainless steel wire with a rectangular cross section of .0015 inches in thickness and .004 inch in width.
In this embodimentj the 3 mm stent is constructed with a stainless steel wire of rectangular cross section with .002 inch thickness and .004 inch width. A 3.5 mm stent is constructed with either a .002 inch thickness and.004 inch;width, or a .002 inch thickness and .005 inch to .007 inch width.
The wires that are used for the braid of the stent portion can be fragile due to their small size and care should be exercised in the manufacturing process. This is particularly true for the small~r , ,. :- .-.: - ~ .
2~8~g2 wires such as the .003 inch round or the .0008 to .0015 thickness flat wires.
In this embodiment, the wire used in each of the aforementioned braiding operations is 304 stainless steel in a spring temper. The specific wire used is the Hyten (T~) wire available from Fort Wayne Netals of Fort Wayne, Indiana. Additionally, any one or more or and in an embodiment 2, 3, or 4 of the 8 wires that comprise the braid may be made of an alloy of 92%
platinum and 8% tungsten for the purpose of providing radiopacity. These alloys may are commercially available from a number of sources, such as Sigmund Cohn Corp. of Mount Vernon, N.Y., or California Fine Wire of Grover City, California.
The braiding process of the present invention requires modification of a commercially available braiding machine to achieve the desired consistency and braid density. In this embodiment, for both the round and the flat wires, the braid pattern is composed of 8 wires. Braiding machines range in size from 16 carriers to 100 carriers. The braiding machine used for the manufacture of the stent described herein is a modified KoKobun SL~4-16 braider available from Wardwell Braiding Machine Co. of Rhode Island, NY.
This same company also manufacturers a series of hraiders under the New England Butt trade name. The braiders may be manufactured to accommodate 4, 6, 8, 10, 12, 16, or 24 bobbins in the machine groups d~fined as NE Butt #1, #2, or the B-11-8. These are all very small bench top versions that are used for small fibers or wire when fragile tensioning is required. The KoKobun is similar to the New England #2. The N E Butt B-9 which is a New England But~ #1 could conc~ivably be 2~68~82 modified to make a 6 or a 5 wire braid which would may also be used for this application.
Machine modifications include the removal of ~ of the 16 carriages, as well as the installation of ultra light tensioning springs on the braider carriages. Additionally the tent angle (i.e. the angle with which the wires approach the central core on which the braid is being installed) normally is free to float up and down as the braiding wire position and rate equilibrate on the central core. For the application of flat wire, the wire may tend to get caught on other wires which are being applied in the opposing direction. The wires then would get flipped over every few linear inches of braid therefore making the segment unusable or incorporatable within the catheter. This problem may be eliminated by providing an angled guide made of a low friction material such as teflon and containing the angle for which the desired tent angle should be guided.
The size and density of the stent is controlled by three variables: the size of the central core to which the braid is being applied; the rate of advancement of the central core through the braid region; and the angular velocity of the braiding carriages. These variables relative to each other determine the "pick" (number of wire group intersections per inch) density of the braid pattern~
These variables also determine the size of the stent that will be manufactured.
In this embodiment, a 2.0 mm stent is made on a central core with a size of .050 inches and a density of 10 per inch. When removed from the core the stent will spring from the I.D. of ~055 to 2.0 mm an~ have a 2~8~82 pick density of approximately of 7 to 15 per inch or approximately .14 to .07 inches between groups or 3.6 mm to 1.8 mm. The de~ree for which the stent expands when removed from the core depends on the pick density during the braiding operation.
The table below outlines the expanded pick densities for the individual stent configurations. The braiding machine us~d must be modified so that the take up velocity of the central core and the radial velocity may be adjusted very precisely to achieve the exact density required. Due to the addition of the guide, as explained above, the density of the braid will not be allowed to assume its own pattern density by climbing up and down the central core, but instead will assume 15 the required density.
size core size pic distance when expanded 2.0 .050 1.8 to 3.6 mm 2.5 .055 1.8 to 3.6 mm 3.0 .062 1.8 to 3.6 mm 03.5 .068 1.~ to 3.6 mm From the table, the desired density in this embodiment is obtained by placing the bridges 1.8 to 3.6 mm apart. Rs mentioned above and unlike a dilation device, an feature of the temporary stent is that it is highly perfusable. This is accomplished in part by minimizing the density of metal within the vessel which may restrict the blood flow both though the ends of the stent and also radially from the sides of the stent. This is important because frequently side branches to the blood vessel are contained in the stent region and flow must exit the stent to keep these side branches : ~ : ' .': .:
.
2 ~ 8 2 perfused. The area or size of the stent should be minimized to maximize perfusion while maintaining sufficient structural support for a flap or other damaged part of the vessel.
The stent portion should not only be perfusable to allow blood flow therethrough, but should also minimize surfaces upon which a thrombus might form. The vascular system is very active with respect to clot formation once a vessel has been damaged or subjected to other trauma such as during an angioplasty~ Any device that is installed for more than a faw minutes is susceptible to clot formation. Because in some embodiments, the temporary stent may be used ~or up to several ~ays, it should also provide for minimization of clot ~ormation.
One way the temporary stent minimizes clot formation is by preparation of the surfaces of the wires of the stent portion. The wires of the braid in this embodiment are made of rectangular wires braided into a 4, or 8 wire braid and rectangular wire may, by reason of the manufacturing processes, have edges that are very and/or sharp. The wire is made by initially drawing it throuyh a die in order to form the specific size that is desired. During this process the temper of the spring may be modified by the cold work that is being induced into the wire from the forceful shaping of the wire. In the case of the HyTen 304 SS wire, the spring 3Q tempers are being achieved with pressures which are substantially greater than 300,000 psi. This spring temper is very desirable from the standpoint of imparting desirable properties to the stent.
~. , ~ a ~ 2 Specifically, the stent must be resilient to return from its initial contracted configuration to the full expanded state with only a minimal application o~ external force. The temper is relevant to the fabrication process and ultimately to the product performance.
The edges formed on the flat wire are rounded off. The method used to radius the corners of the flat wire is electropolishing which removes edges or protrusions of the material and passivates the metal without altering the bulk properties of the metal. The metal is left in a passive state by the electropolishing process and the metal is also highly resistant to corrosion.
The electropolishing operation requires the use of an electrolytic fluid. This fluid must dissolve the products ~formed on the work piece which in this case is the metal stent surface) by electro-chemical action. High current densities of 1000-5000 amps per square inch are maintained between the workpiece and a cathoda. A DC power supply is used to provide the required power. The rate of removal is reyulated by the current flow through the work piece. Corners or asperities extending from the surface of the work piece have a greater projected surface area/volume ratio than does the flat area. For this reason, material is removed from such regions at an accelerated rate.
Further, this operation is ideal for smoothing the flat wire in the ~tent region and radiusing the corners which other wire would exhibit sufficient sharpness to potentially scrape the endothelial cells from the inside of the vessel thus promoting - : , :: :~ .: :-: : . : , :. : , : : , 2~8~8~
thrombus. After electropolishing, a flat wire 79 may possess a rounded cornered cross sectional profile, as depicted in Figure 10.
The electropolishing operation may be performed as follows. The electropolishing solution should be selected which meets the operational requirements. An acidic solution should be selected which is compatible with the electro-chemical characteristics such that material may be removed without the production of carbides or other metal impurities on the surface which will result in corrosion. A direct current (DC) power supply is provided to provide the electromotive potential required to force the electrochemical sacrifice of metal from the surface. The positive (~) terminal (the anode) is attached to the workpiece, and the negative terminal is attached to a non-corrosive negative (-) terminal piece (the cathode).
The stainless steel wire requires a voltage of approximately 5 volts to perform the polishing vperation. This voltage is dep~ndent on the electropolishing solution being used as the electrolyte. The solution being used in this embodiment is a solution of phosphoric acid, citric acid, deionized water, and ethyl alcohol. The operation is performPd at an elevated temperature in order to increase the rate of metal removal and provide for the smoothest possible surface. Other electrolytes are available additionally that are effective on the stainless steel. These solutions are frequently combinations of alcohol~ multiple acids, and water. Sulfuric acid based solutions are frequently used in electropolishing of stainless :, ~. , -. :
-` 20~3~82 steel. If other metals are used in whole or in part in the braid, e.g. platinum or tungsten, in order to provide for radiopacity, modifications to the method may be appropriate. Electropolishing solutions used on the platinum-tungsten material used on the rectangular wire used in the braid may be polished using a HF acid solution in the same manner as described above, or may be mechanically radiused prior to incorporation in the braid by winding the wire from spool to spool and passing over a sequence of polishing wheels. This may be preferred to avoid dealing with HF acid. Many of the other metals which alternatively will provide opacity under X-ray also are quite noble and require HF acid for polishing. The mechanical polishing method is preferable for these metals.
The ease of electropolishing the stainless steel and the smooth-burr free surface that is provided makes this the method over mechanical removal. It must be understood that mechanical removal is also possible and relatively easy with the stainless steel.
The stainless steel that is in the austenite alloys provides a self-repairing oxide film which prevents corrosion. Passivity may be diminished or lost by any process in which a localized oxygen withdrawal occurs by any means.
Heating or chemical reactions are capable of relieving this oxygen. The passive state may be restored to the material by exposing th~ material to an oxidizing environment such as nitric acid. The passivation state may be altered during the electropolishing operation if the parameters are not ~ - 34 -2 ~ 8 2 closely controlled. The voltage driving the chemical reaction will affect the passive state of the remaining surface. In the case of the process utilizing the phosphoric acid solution the voltage and temperature at which the process is operated at is 80 degrees celsius and 5 +/ .25 volts. The specific solution composition is 757.6 c~/liter phosphoric acid, 181.8 cc/liter de-ionized water, 60.6 cctliter denatured alcohol, and 303.0 grams/liter citric acid.
In addition to the electropolishing step described above, clot formation can further be minimized by the application of one or more anti-thrombogenic coatings. In this embodiment, the braided wires are coated in two layers with a silicone oil solution. The surface is treated twice to achieve complete surface coveraga. Since the engagement of the braided stent s~ction results in a relative movement of the individual wires with 2Q respect to each other, the stent region is coated in both an expanded and contracted configuration. The coating used in this embodiment is Dow Corning (R) MDX4-4159 silicone fluid. The coating may be applied in accordance with the instructions in Dow Corning Bulletin 51-599 (July 1982) for the MDX4 4159 silicone fluid which is incorporated herein by reference.
Although a braid is a presently preferred construction for the perfusable stent portion 14, oth2r alternative embodiments may include a plurality of parallel wires forming a hollow cylindrical tube each wire substantially parallel to the axis of the hollow cylindrical tube. In this - ; ., : :.. :
- .- :, : :: ,: : .: ~: -., , :
2~6~5~2 alternative construction, at the ends of the elongate hollow tube formed by the plurality of wires, each wire would include an oblique bend so that each wire could be connected to the actuator portion which is aligned with the axis of the hollow tube formed by the wires. Relative displacement between the ends of the wires would cause the oblique angles at the end of each wire to change thereby increasing or decreasing the diameter of the hollow tube to enable placement or removal of the stent from the vascular region of the patient's body. Other alternative constructions for the stent portion may also be provided.
In accordance with the present embodiment, it is presently preferred to utilize a temporary stent of a specific and selected expanded size suitable for the region of the vascular system in which it is intended to be installed. Accordingly, it is presently intended with this embodiment to utilize dif~erent sizes of stents where different expanded sizes are needed. Alternatively, where th~re is a need to apply a temporary stent in a small size vessel, instead of using a small size temporary stent, it is possible to utilize a large size temporary stent (i.e. one that is expandable to a large diameter) but to only expand it partially to an intermediate expanded diameter size. This could be accomplished by fixing the proximal ends of the actuator portion 18 and the inner elongate member 26 at an intermediate position between where the catheter is fully compresssd and where it is fully expanded.
, . . . .
`` 2 ~ 8 2 These dimensions provided above are intended as approximate and other sizes and dimensions may be selected and designed in accordance with the teachings of the present invention.
In a most preferred embodiment, the temporary stent is operated by means of a manifold assembly 220, as depicted in Figures 12 and 13.
Referring to Figure 12, the manifold assembly 220 connects to the proximal end of the elongate member 14. The man.ifold assembly 220 includes a body portion 222 made of polycarbonate. The body portion 222 includes a reservoir 224 located internally thereto. An insert 226 is located in the body portion 222 and forms a distal end wall of the reservoir 224. A first 0-ring 228 forms a seal between the insert 228 and the body portion 222.
The proximal portion of ~he outer catheter 54 communicates with the reservoir 224 via a distal opening 230 of the body portion 222. A strain relief member 232 fits over the proximal end of the outer catheter 54 at the location where it enters the distal opening 230 of the body portion 222. The strain relief member 232 is preferably conically shaped and made of pellethaneO The proximal end of the outer catheter 54 terminates at the reservoir 22~.
The body portion 222 also includes a port 234 communicating with the reservoir via a luer connection 236. Fluids such as medicines can be supplied via the port 234. Fluids supplied via the port 234 are thereby transported within the lumen of the outer catheter 54 in the annular region between -.: . . , .: . . : . ....
2~68~2 the outer catheter 54 and the inner catheter 44 and discharged into the vessel at the distal termination of the outer catheter 54 at the proximal end o~ the stent portion 14.
A hypotube 238 is fixed to the outer diametsr of the inner catheter 44. The hypotube 238 is preferably made of stainless steel. The proximal end of the hypotube 238 extends through an opening 240 through the insert 226. A second 0-ring 242 fits between the hypotube 238 and the insert 226 to form a fluid tight seal.
The proximal end of the hypotube 238 terminates in an actuator member 244. Referring to Figure 13, the actuator member 244 includes wings 246 that fit in corresponding grooves 248 of the body portion 222 so that the actuator member 244 can move longitudinally relative to the body portion 222 but not rotationally. The wings 246 also provide for structural support between the body portion 222 and the actuator member 244. The actuator member 244 includes a luer connection 250 on a distal end that communicates with the lumen of the inner catheter 44 via the lumen of the hypotube 238. In a preferred embodiment, the lumen of the inner catheter 44 is used for a guide wire so that the temporary stent can be positioned in the vascular system by means of an over-the-wire procedure. (In alternative embodiments, the temporary stent may use a fixed wire or a rapid exchange construction for positioning in the patient's vessel).
The actuator member 244 i5 sized and adapted for limited movement longitudinally in the body portion 222. Referring again to Figure 12, a 2 0 6 8 ~ 8 2 locking member 252, which in a pre~erred embodiment is a nut comprised of mating pieces of polycarbonate, f its over the proximal end of the body portion 222. The nut 252 includes a detente 5 that engages one of the wings 246 of the actuator member 244 in order to lock it in either a fully extended or a fully retracted position with respect to the body portion 222. When the actuator member 244 is ~ully retracted proximally with respect to the body portion 222, this corresponds to the at-rest configuration of the stent portion in which the stent assumes its expanded configuration. When the actuator member 244 is fully extended distally with respect to the body portion 222, this corresponds to the contracted configuration of the stent such as when the stent is being positioned in or removed from the vessel.
~ eferring to Figure 6, there is depicted the distal end of another embodiment of the present 20 invention~ The proximal end (not shown) could function similarly as in the first described embodiment. In this embodiment, a temporary stent 80 has a stent portion 82 and a actuator portion 84.
The stent portion 82 is connected to the actuator portion 84 at a proximal end 86 of the stent portion 82. An inner elongate member 88 extPnds throuqh the stent portion 82 and th~ actuator portion 84. As in the previous embodiment the inner elongate member 88 is connected to a distal end 90 of the stent po.rtion 82. Also, as in the previous embodiment, the inner elongate member 88 may be moved relative to the actuator portion 84 to cause expansion and contraction of the stent portion 82~
, :: , ,.. :.... . .. .
: :: . , ., ., :
,. : : : ~: , ,,: . ~, ;. ~: : - : ; . ~:
In this embodiment, the inner elonga~e member 88 further includes a guidewire tip 92 that extends distally from the distal end 90 of the stent portion 82. The guide wire tip 92 is flexible and formable and includes a rounded portion 94. The guidewire tip 92 facilitates positioning the temporary stent 80 in the vascular system. In Figure 4, the guidewire tip 92 is depicted having a curvature although it should be understood that the guidewire would normally be provided in a straightened position and that the curvature may be imparted by a physician prior to insertion into the vascular system of the patient in order to facilitate positioning of the stent. The guidewire tip 92 may assume a curvature such as depicted during its positioniny in a tortuous vessel path.
In this embodiment, the temporary stent ~0 may be positioned by means of the guidewire tip 92 instead of over a separate guidewire that is located the inside an inner catheter (e.g. lumen 5Q of inner catheter 44 in the first embodiment).
Referring to Figures 7 and 8, there is depicted another embodiment of the present invention. In Figures 7 and 8, a temporary stent 100 includes a stent portion 102 and a actuator portion 104 connected to each other at a proximal end 106 of the stent portion 10~. In this embodiment, a distal end 10~ of the stent portion 102 includes a cylindrical shaft 110 having a cylindrical opening 11~ therethrough. The cylindrical shaft 110 includes at least one bearing surface 116 thereupon. An inner elongate number 118 is located in the hollow tube of the formed by the ~ , . . , ; , . - . . ,. :, . .. ..
.: : : ; .. , .. : , ~ - ... .
2~8~82 stent portion 102 and extends proximally as in the previous embodiments. Unlike the previous embodiments, the inner elongate member 118 is not fixed to stent portion 102. Instead, the inner elongate portion 118 has a narrow distal portion 120 positioned to be slidingly received in the opening 112 of the shaft 110. A first shoulder 122 on the inner elongate member 118 is located to bear upon the surface 116 when the inner elongate member 118 is moved distally. The inner elongate member 118 also includes a second shoulder 126 formed distally of the narrow distal section 120. The second shoulder 126 is located to bear upon another surface 128 of the inner elongate member 118. Proximal movement of the inner elongate member 118 causes the shoulder 126 to bear upon the surface 128 causing expansion of the stent portion 102. As shown in Figure 8, the second shoulder 126 may form part of a guide wire tip 130. ~owever, other configurations for the tip are also suitable. With the embodiment of the invention depicted in Figures 7 and 8, limited axial movement of the inner elongate member 118 is provided which may be suitable and desirable Eor positioning and removal of the removable stent.
As shown in Figures 7 and 8, tha surfaces 116 and 128 and the shoulders 122 and 126 may be formed to prevent removal of the inner elongate member 118 from the actuator portion 104 and stent portion 102 although removability may be provided by alignment of the shoulders 106 with the bearing surface 128.
As in the previously described embodiment, with this embodiment a separate guide wire is not required to .. . .
2~8~82 position the temporary stent inside the vascular system.
As described above, because the temporary stent will be left in the vascular system for a period of time, the temporary stent should avoid or minimize clotting or platelet aggregation in and around the stent portion. Also, it is advantageous to reduce the tendency of the stent to permanently adhere to the inner surface of the vascular walls in order to facilitate removal of the stent. This may be accomplished by providing or imparting to the temporary stent properties that will minimize these tendencies.
In one alternative embodiment, the stent portion includes a coating of a slow release polymer having anti-thrombogenic properties. Such polymers include drugs such as urokinase, heparin, antithrombin III or other thrombon-resistive agents.
The polymer used~may be polyethylene or a polyolefin.~
The natural surface charge that is present intrinsically on a material is considered to be a factor in the chain of successive events that results in the formation of mural thrombus on an artificial surface. Although, the blood coagulation cascade is complex and not fully understood, it is accepted that on an artificial surface, characteristics such as low surface energy ~i.e.
hydrophobic), and the electro-negativity of the surface af~ect the initial events that are important to subsaquent rPactions or svents that result in the formation of thrombus. For this reason, in this embodiment, the surface is coated with a silicone 20~o~82 oil solution which is of a low sur~ace energy.
Other alternative coatings that will provide relative thromboresistance include teflon, and pyrolytic carbon. While pyrolytic carbon has a relatively high surface energy of approximately 50 dyne/cm which is generally not considered thromboresistant, upon exposure to blood it has been observed to present a change to about 30 dyne/cm.
This is considered to be thromboresistant and is ~0 thus a widely used material in coating of metal heart valves. The relative success of the stent in placement in vivo is dependent upon the ability to manipulate the surface characteristics to "tune" the device to the requirements that are present but not fully understood in the blood chemistry reactions.
Other methods may be used to provide this property. For examplP, the surface of the stent portion may effectively be charged and polarized to prevent the sequence of events that results in clot formation. By installing an external ground plane to the patient and placing a lead to the metal surface, the braid may be energized such that it is essentially an insulated capacitor which will provide the surface charge of desired magnitude, and polarity. The voltage level supplied to the wire is effectively additive to the natural negativity of the surface. The net potential may be effectively adjusted to a zero, positive, or negative charge.
R~ferring to Figure 9, a charge is imparted to the stent portion. The DC power supply 150 is located outside the vascular system. Only a small current is necessary (for example, less than 50 microamps).
This could be provided by a small battery such as a ~068~82 watch battery. This would be sufficient to impart a charge to the stent portion to minimize the tendency for clotting materials to form on the stent portion.
The polarity may be selected based upon consider-ation of factors, such as material, coating,medication, etc. A lead 152 is connected to the stent portion of the temporary stent and the other lead 154 i~ connected to the body 156 of the patient. As described above, the proximal end of the stainless steel braid comprising the stent portion could extend all the way to the proximal end of the outer catheter to form part of, or to connect to, lead 152. The braid may provide a pathway proximally to the manifold which provides an electrically conductive pathway so that a surface charge may be placed which in effect overrides the natural electro-negative characteristics of the stainless steel metal surface from which the braid ~ is formed. Alternatively, the wires that make up the stent portion~may connect to a lead at a point proximally from the proximal end of the stent portion and the lead could extend proximally.
Additionally by providing a waveform polarizing ~unction, the stent surface may be polarized with a time varying potential. The application of a high frequency current in the kilohert~ to the megahertz range is a procedure that has been tested for healing of wounds. The construction of the stent portion is designed to have a periodic surface contact with the wounded vessel~ and a network for applying desired voltage, and polarities and frequencies to an Lntimate contact with the wounded vessel. The device may be - - : : : , . ~ : . : ,:: : , 2~8~2 constructed to apply current to the stent of O ko 20 micro amp to the surface when an uncoated surface is used or whPn a noble coating such as gold or platinum is applied. Gold may be applied by standard vapor deposition process known as sputter coating, or by an electro-chemical plating process.
Platinum is normally electro-plated.
Anoth~r method for imparting a charge to the stent portion is by means of an RF signal. By this method, the proximal end of the stent portion will be connected to a RF source.
It is intended that the foregoing detailed description be regarded as illustrative rather than limiting and that it is understood that the following claims including all equivalents are intended to define the scope of the invention.
.. .- i ; ,. ~
: ~ . . , : : ~ . :
. . :,. . : .
Angioplasty is a procedure in which a balloon is positioned on the inside of the artery at the site of the lesion and expanded in order to compress the materials at the lesion and thus open the restricted area in the artery. In this procedure, an elastic balloon is attached to one end of a small diameter flexible catheter which includes means for inflating the balloon from the other end of the catheter. The catheter is maneuvered through the patient's vessels to the site of the lesion with the balloon in uninflated form. When the uninflated balloon is properly positioned at the lesion, the balloon is then inflated to dilatate the restricted area.
Atherectomy is a procedure in which a small cutting tool is attached to the end of a small diameter flexible catheter and maneuvered through the patient's arterial system to the site of the lesion in the diseased artery. When the cutting tool is properly positioned, the tool is used to cut and remove the deposits from the surface of the diseased artery.
Although these two procedures provida less traumatic alternatives to bypass surgery, they are not without risk. It is possible that following procedures such as angioplasty or atherectomy the artery or blood vessel may collapse or be susceptihle to constriction.
In some instances it may also be necessary to abort or "bail out" procedures such as angioplasty or atherectomy due to some type of unexpected complication.
:
`~ 20~82 In these situations it is necessary to maintain the integrity of the region of the artery until the artery is repaired or stabilizes. That is, following some angioplasty or atherectomy procedures or in a "bail-out" situation, it may be necessary to provide support to a artery or blood vessel on a temporary basis while there is an immediate risk that the region may collapse. This support must be provided until the region is repaired or stabilized. To provide this support, a device known as a stent may be installed at the desired region. A stent is a device which is used to hold or maintain the diameter of the artery or vessel.
Although some stents are available in the art, these are generally of the type intended for permanent use. This type of permanent stent is implanted in a patient's vascular system and remains in -place after the procedure or operation. Such permanent types of stents are shown, for example, in U.S. Patent Nos. 4,913,141, 4,878,906, 4,856,516 and 4,820,298.
These permanent type of stents may not always be desir~d for the situations described above. First, it may be unnecessary and even undesirable to install a permanent device when only temporary support is needed.
Further, these permanent type of stents may require a relatively complicated procedure to install. Further, use of permanent stents results in extended hospital o~servation and recovery time. Additionally, a complement of drug therapies are required in order to offset the bioreaction resulting in thrombus formation or smooth muscle cell proliferation on the stent surface. These drug therapies may be required for a significant period of time until new normal endothelial :: : .: .: . ;.- : , . .: . : .. : : - :: : . . : :: :
20~8582 cells have ~ormed. In situations such as a "bail-out it is desirable for the physician to have the ability to quickly maneuver the stent to the desired location and quickly and easily place the stent in its operating mode.
A temporary stent on the other hand may be particularly useful in situations where it is intended to be used in the patient only for several minutes or days and then removed. For example, use of a temporary stent in a bail-out situation will enable the physician to defer a more complicated procedure until a patient's condition is more stable, or in some cases eliminate further procedures by resecuring the vessel geometry which allows near normal blood flow.
A temporary stent may have particular usefulness in situations such as when an intimal flap is encountered or during occurrrences of vasoconstriction or vasospasm or in situations in which there is a potential for such conditions to occur such as following angioplasty. An intimal flap occurs when a portion of the vessel wall partially or completely tears off and hangs down into the blood flow path. An intimal flap may occur during or after an angioplasty procedure. If the flap is large, it may entirely occlude the vessel lumen. The flap may heal itself if it can be maintained in place against the vessel from which it tore.
Vasoconstriction or vasospasm also may occur during or after angioplasty. Vasoconstriction or vasospasm in many cases may accompany the occurrence of an intimal flap, but in many other cases, vasoconstriction or vasospasm may occur independent of an intimal flap. During vasoconstriction or vasospasm, muscles around th~ vessel contract and can partially or completPly occlude the vessel. If the vessel can be maintained open, vasoconstriction or vasospasm may cease after a period of time. Medicines may be administered to treat the vasoconstriction or vasospasm. Whereas a small force may be sufficient to maintain an intimal flap against the vessel wall and maintain blood flow, a significantly greater force would usually be needed to keep a vessel open during an episode of vasoconstriction or vasospasm.
It is essential that a temporary stent be relatively easy to both install and remove. Since the temporary stent remains in place for a period of time, it is important that the temporary stent not block the flow of blood through the vessel. That is, the blood must be able to travel through the vessel in which the temporary stent is installed while the stent is in place. Further, since the lesions often occur at the intersection of two vessels, in order to position the temporary stent it is may be necessary to place the stent across the intersection. Therefore, it is critical that the stent provide a flow path radially as well as axially or longitudinally. This arrangement will allow blood flow to both of the intersecting arteries.
It is also desirable to have the ability to deliver medicines to the vessel either upstream or downstream of temporary stent while the stent is in place.
Since th~ temporary stent will be removed after a period of time, it is important that the temporary stent not permanently adhere to the inner walls of the vessel in which it is placed. In addition, a temporary stent should have no tendency, or only a minimal tendency, to cause clotting.
Accordingly, it is an object of the present invention to provide a stent that may be placed temporarily in a patient's vascular system and which is readily rPmovable.
SUMMARY OF THE INVENTION
The present invention relates to a temporary stent for supporting a region of a vessel in a body comprising a composite portion and an actuator portion and methods for the use and manufacture thereof. The composite stent portion is comprised of an elongate perfusable vessel supportiny portion adapted to be configurable between a reduced si2e for plac~ment in the vessel and removal therefrom and an expanded size for structurally supporting the vessel. The composite stent portion is comprised of a plurality of resilient metallic wires coated with a polymeric material to provide stability for both lifting and maintaining a vessel.
With this arrangement, the temporary stent may be positioned in the desired region and may be used to maintain vessel patency during the occurrence of an intimal flapl vasoconstriction, vasospasm, or other conditions that occlude the vessel lumen or when there is a potential that such conditions may occur such as following angioplasty.
BRIEF DESCRIPTION OF THE FIGURES `
Figure 1 depicts a first embodiment of the present invention.
~' . ; . ................. :
. ,. . , ~ ;
.
~068~2 Figure 2 shows a distal portion o~ the embodiment depicted in Figure 1 with the stent portion in a reduced contracted configuration.
Figure 3 shows a distal portion of the embodiment depicted in Figure 1 with the stent portion in an expanded configuration.
Figure 4 is a longitudinal sectional view showing a portion of the embodiment depicted in Figure 1.
Figure 5 is a longitudinal sectional view showing a portion of the embodiment depicted in Figure 1.
Figure 6 depicts a distal portion of another embodiment of the present invention.
Figure 7 depicts a distal portion of another embodiment of the present invention in a contracted configuration.
Figure 8 depicts the distal portion of the embodiment shown in Figure 7 in an expanded configuration.
Figure 9 depicts another embodiment of the present invention.
Figure 10 is a cross section of an embodiment of a wire component along lines 10-10' of Figure 2.
Figure 11 is a lvngitudinal sectional view of a distal portion of another embodiment of the present invention.
Figure 12 is a cross section of a proximal portion of an embodiment of the present invention showing aspects of an embodiment of the manifold actuator assembly.
Figure 13 is a perspective view of a portion of th~ manifold actuator assembly of Figure 12.
2~8~2 DETAILED DESCRIPTION OF THE
PRESENTLY PREFERRED EMBODIMENTS
Ref~rring to Figure 1, there is depicted a first embodiment of ~he present invention. The embodiment of Figure 1 is a temporary stent 10 which can be placed in the vascular system of a patient after a procedure such as angioplasty, atherectomy or other interventional therapies. Although the temporary stent 10 is particularly useful in procedures involving blood lo vessels, it may be used in other fluid carrying vessels in the patient's body. As used herein, the term "vascular system" refers to a vessel for conveying body fluids. The temporary stent 10 is intended for placement in a vascular system for limited durations of time from several minutes to up to several days.
In the embodiment of the invention depicted in Figure 1, the temporary stent 10 includes a perfusable stent portion 14 and an actuator portion 18.
The stent portion 14 is connected to a distal end 20 of the actuator portion 18. When the temporary stent 10 is being used in a patient, the actuator portion ~8 extends proximally from its connection to the stent portion 14 through the vascular system and out of the body of the patient. In one embodiment, the proximal end 22 of the actuator portion 18 extends out the body of the patient is connected to one or more, ror example two, manifolds 24 and 26.
The stent portion 14 is expandable and contractable so that it can be positioned in the vascular system at the specific location where needed and then expanded to an appropriate size (i.~.
approximately the same diameter as the vessel in the region where placed) thus supporting that vascular .
:- : -, . ::, , , ~ 2068~82 g region. When in its expanded configura~ion, the ~ten~
portion 14 provides support to the vascular walls thereby preventing constriction of the vascular region in which it i5 located and maintaining the vascular lumen open.
The construction and materials for the stent portion 1~ should provide that the stent be perfusable, i.e. it should allow blood flow therethrough both in the axial direction of the vessel to maintain blood flow through the region in which the stent is located as well as in the radial direction so that any vessels that branch off from the region of the vessel into which the stent portion is placed will not be occluded.
Thus, the stent portion 14 should be relatively transparent to blood flow in order to maintain vascular function while at the same time providing support for the vessel walls in the region where it is located.
Expansion and contraction of the stent portion 14 inside the patient's body may be accomplished from outside of the patient's body by means of manipulation of the actuator portion 18 from the proximal end 22 thereof which is located outside the patient's body. In this embodiment, the actuator portion 18 comprises a first elongate member 28 that connects to a proximal end 30 of the stent portion 14 and a second elongate member 32 that connects to the distal end 34 of the stent portion 14. Relative movement of the first elongate member 28 and the second elongate member 32 causes expansion and contraction of the stent portion 14, as explained in more detail below. The distaI end 20 of the actuator portion ~8 remains in place in the body during the period of time that the stent portion 14 is in place in the vascular _ 9 _ . . ~ , .
. . v ~a~s2 system and during this time the proximal end 22 oP the actuator portion 18 extends out of the patient's body.
At the proximal end of the actuator portion 1~, the first elongate member 28 terminates at a manifold 24 and the second elongate member 32 terminates at the manifold 26. In one embodiment, these manifolds include hemostatic valves and Y-connecters for administering fluids, such as medicines through these manifolds, as described below.
In a preferred embodiment, the stent portion 14 is comprised of a braid made of a plurality of helically wound wires forming an elongated hollow tube.
Typically, half of the wires forming this tube will be wound in one helical direction and the other half will be wound in the opposite helical direction and interwoven with the first half. Braiding of these wires provides for an elongated, expandable hollow tube that can, in a preferred embodiment, increase in diameter when the ends of the hollow tube are moved closer relative to each other and decrease in diameter when the ends of the hollow tube are move apart relative to each other. The ratio by which the stent portion expands depends upon the spacing betwPen adjacent wires that make up the braid as well as the cross sectional dimensions of each of the individual wires.
The stent portion 14 may be provided in a wide range of sizes and stiffnesses to meet the requirements for use with different lesions, flaps, or vasoconstrictions in a patient's vascular system. The stent portion 14 is constructed to be flexible enough to traverse its way to the region of the vascular system where it is to be located and expanded to 2~8~82 : `
provide support for the region of ~he vascular system, such as the site of previous angioplasty or other treatment.
The stent portion 14 terminates in a distal end 34. Located inside the hollow tube of the stent portion 14 is the second (or inner) elongate member 32.
The second elongate member 32 is connected to the distal end 34 of the stent portion 14, as explained below. The second elongate member 32 extends lo proximally from its connection to the distal end 34 of the stent portion 14, through the hollow tube of the stent portion 14, and through an inner lumen of the first elongate member 28 to the proximal end thereof.
In accordance with this embodiment, relative movement between the first elongate member 28 and the second elongate member 32 causes corresponding movement of the proximal end 30 and distal end 34 of the stent portion 14 thus in turn causing expansion or contraction of the diameter of the elongate hollow tube of the stent portion 14.
In Figure 2, the temporary stent 10 is depicted in its constricted ronfiguration with the elongate hollow tube of the stent portion 14 having a reduced diameter. In this configuration, the second elongate member 32 extends distally from the first elongate member 28 so that the length of the stent portion 14 is L1. In Figure 3, the second elongate member 32 is positioned at a location more proximate relative to the first elongate member 28 than in Figure 2 (i~e., in the direction of arrow 35) causing the length of the stent portion 14 to be equal to L2 ~L2 being less than Ll). In the process of moving proximally r~lative to the first elongate member 28, , .- : - , ,.,~ ., : , :
2~6~582 the second elongate member 32 causes the proximal and distal ends 30 and 34, respectively, of the stent portion 14 to move relatively closer together thus causing the diameter of the elongate hollow tube of the stent portion 14 to expand to a dimension suitable for supporting a region of the vascular system. The temporary stent 10 can be maintained in this expanded configuration by fixing the proximal ends of the first and second elongate members 28 and 32 for the duration of the time that the temporary stent 10 is maintained in the vascular system. This may be done by attaching a clamp 39 or similar device to the proximal ends of the first elongate member 28 and the second elongate member 32 at the manifolds 24 and 26. These two elongate members can be later disengaged from each other to permit reducing the diameter of the temporary stent 10 for removal thereof from the body. In alternative embodiments, the first and second elongate mem~ers may be fixed by means of an actuator manifold, as described below.
In order to provide a means by which the position of the temporary stent 10 in the body of the patient can be determined, one or more radiopaque markers, e.g. 40 and 41 may be located on a distal region of the stent, for example on a distal region of the second elongate member 32O These markers may be bands of radiopaque materials such as platinum, tantalum, gold, tungsten or a tungsten-iridium alloy.
Referring to Figure 11, there is illustrated a distal portion of a most preferred embodiment 200 for incorporating radiopaque markers for use in an embodiment of the temporary stent. In this embodiment, there are three radiopaque markers associated with the 20685~2 distal portion of the temporary stent. A first marker 202 is located at or adjacent to a distal end of the stent portion 14. A second marker ~04 is located at or adjacent to a proximal end of the stent portion 14. By means of these two markers 202 and 204, the length of the stent portion 14 can be determined during expansion and contrackion. A third marker 206 is fixed to the second elongate member 32 in the region corresponding to the stent portion 14. Accordingly, by observing the position of the third marker 206 relative to the first and second markers 20~ and 204, it is possible to obtain continuous feedback of the stent deployment during expansion and contraction. In a preferred embodiment, the third marker 206 is approximately adjacent to the second marker 204 when the stent portion is fully expanded and is approximately just proximal of the midline of the stent portion 14 when the stent portion 14 i5 contracted. In the preferred embodiment, the markers are made of platinum with 10%
iridium.
In a most preferred embodiment, the markers are formed of wire that is wound around the proximal and distal ends of the braid and also serve the funrtion of securing the proximal end of the braid to the first elongate member 28 and the distal end of the braid to the second elongate member 32. In the preferred embodiment, the braid is pulled down on a mandrel and the marker wire is coil wound around the ends of the braid. Then, the coils are clipped and brazed. In this manner, the braid is both secured to the catheters elongate member and markers are provided.
Instead of brazing, the markers may be secured to the elongate members by means of welding, soldering, 2~S82 adhesives, or other means. The third marker, i.e. the marker located on the inner catheter 54, may be installed similarly except that it will not be connected to the braid.
Re~erring to Figure 4, there is depicted a longitudinal cross section of the distal end of the se~ond elongate member 32. In this embodiment, the second elongate member 32 is an inner catheter 44. As depicted in Figure 2, the distal end 34 of the stent portion 14 surrounds an outside wall of the inner catheter 44. A collar 46 surrounds and affixes the distal ends of the wires that make up ths braid of the stent portion 14 to the distal end Qf the inner catheter 44 (i.e. first elongate member 32). The collar 46 may be made of a balloon tubing polyolefin or other ultra-thin wall polymers. The collar 46 may be heated to fuse to the outer wall of the inner catheter 44 or connected thereto by an adhesive or other suitable means. In this manner, the distal end 34 of the stent portion 14 may be securely fixed to the inner catheter 44 suitably for the duration of the use of the temporary stent lo. A distal tip 48 of the temporary stent 10 is formed of an extension of the inner catheter 44 distally past the collar 46. This 2 extension may be approximately 0.25 cm. This distal end may have an outer diameter of approximately 0.039 inches. The inner catheter 44 has a lumen 50 therewithin that communicatPs with an opening 52 at the distal tip 48.
Referring to Figure 5, there is a longitudinal ~ectional view depicting a portion o~ the proximal end 30 of the stent portion 14 and the actuator portion 18 and specifically the connection of . .
, :; , , , ~: : , ~ :
2~6~82 the proximal end 30 of the stent portion 14 to the first elongate member 28 of the actuator portion 18.
In this embodiment, the ~irst elongate member 28 is an outer catheter 54. As shown in Figure 5, the outer catheter 54 includes an inner tubular layer 56 and an outer tubular layer 58 that is concentric with the inner tubular layer 56. The outer diameter of the outer catheter 54 would be approximately close to, but may be slightly larger than, the contracted diameter of the stent portion 14. Thus, for coronary appli~ations, the outer catheter 54 may have an outer diameter of approximately 0.039 inches, and for peripheral applications the outer catheter 54 may have a diameter of approximately 2.10 mm. The length of the outer catheter 54 could be made to various sizes to be suitahle for different treatment sites. For coronary applications, the length of the outer catheter 54 would be approximately 175 cm, for example.
In this embodiment, the proximal end 30 of the stent portion 14 is secured between the inner and outer concentric tubular layers 56 and 58 by extending the wires of the braid proximally between these concentric layers. The concentric tubular layers 56 and 58 and the wires of the braid of the stent portion 14 may be bonded together by an appropriate adhesive or by heating. A frictional fit may also be suitable.
Preferably, the wires of the braid terminate proximally at the proximal end of the first elongate member 28.
Alternatively, the wires of the braid may extend the sntire length proximally to the proximal end of the first elongate member 28 or the wires of the braid of the stent portion 14 may extend only a short distance - 2 ~ 8 2 or an intermediate distance proximally between the concentric tubular layers 56 and 58.
In this embodiment, the inner tubular layer 56 terminates a distance proximally from the distal end of the outer tubular layer 58. This enables the outer catheter 54 (i.e., first elongate member 18) to be reduced in diameter in the distal region thereof forming a necked down portion S0 to facilitate positioning the temporary stent 10 in a region of the vascular system. The necked down portion 60 of the outer catheter 54 may be approximately 3 to 30 cm in length.
Referring again to Figure 3, when the stent portion is in its expanded configuration, the proximal 30 and distal 34 ends of the stent portion 14 will assume a proximal and distal truncated conical profile regions 62 and 64. These truncated conical profile regions 62 and 64 taper from a narro~ dimension where the wire braid is affixed to the actuator portion 18 proximally and distally (i.e., first and second elongate members 28 and 32) up to the expanded diameter of the stent portion 14. These regions 62 and 64 may be linearly tapered, but a non-linear taper may also be provided. The type of taper depends upon the type of braiding method used. Because the diameter of the second elongate member 32 is less than the diameter of the first elongate member 18, thP distal tapered region 64 may not correspond exactly in size or slope to the proximal tapered region 62. In both the proximal tapered region 62 and the distal tapered region 64, the braiding method used preferably provides for relatively large distances between adjacent wires to provide correspondingly large openings around and through the - . ,. ~
2~6~$2 plurality of wires at the ends of the stent portion 14 to facilitate blood flow therethrough.
In this embodiment, the temporary stent 10 may be positioned in the vascular region over a guidewire 70 through the lumen 50 of the inner catheter 44. The guidewire 70 may be a standard guidewire suitable for the region of the vascular ~ystem into which the stent will be located. According to this embodiment, the guidewire 70 is positioned in the vascular system across the region where it is desired to install the temporary stent 10. The guidewire 70 may be positioned by standard procedures. The diameter of the lumen 50 of the inner catheter 44 is of a sufficient size to allow the stent portion 14 to be advanced in the vascular system over the guidewire 70.
The temporary stent 10 including the sten~ portion 14 and the distal end of the actuator portion 18 is advanced over the guidewire 70. The lumen 50 of the inner catheter may be compatible with 0.014, 0.016, or 0.018 guidewires for coronary applications and with up to 0.038 guidewires for peripheral applications.
Alternatively, the temporary stent 10 could be located in the vascular region by guidin~ it through a separate catheter (e.g. a delivery catheter) large enough to contain the temporary stent 10 in its contracted configuration.
For coronary applications, the stent portion 14 of this em~odiment is expandable from a siza of approximately 1.25 mm or less to up to approximately 4.0 mm. When used for peripheral applications, the stent portion 14 of the temporary stent 10 may have a contracted diameter of less than approximately 2.0 mm and an Qxpanded diameter of up to approximately 6.0 mmO
~ 17 -:- , , :, . .: ~ : . : :
2~6~82 The length of the stent portion 14 is approximately 2.5 to 5 cm when in its most extended position (i.e. when the diameter of the stent portion 14 is in its contracted configuration). When the diameter of the stent portion is in its expanded configuration~ the length of the stent portion is somewhat less, e.g.
approximately 1.5 to 3.5 cm.
In a most preferred ~mbodiment, the stent portion is provided in two alternative lengths: 25 and 40 mm. These dimensions refer to the length of the stent portion when it is deployed to support a portion of a vessel, i.e. in the expanded configuration.
In this embodiment, fluids such as medicines may be introduced to the vascular system via the lumen 50 of the inner catheter 44 as well as through a lumen 72 of the outer catheter 54 around the inner catheter 44. Medicines introduced via the inner catheter 44 will enter the vascular system at the distal end 48 of the stent portion 14 via opening 52. In this embodiment, sufficient space is provided in the lumen 72 of the outer catheter 54 around the inner catheter 44, so that a second passageway for the introduction of fluids such as medicines to the vascular system is also provided. Medicines introduced via the lumen 72 of the outer catheter 54 will enter the vascular system at the proximal end 30 of the stent portion 14. In this manner, the attending physician has the choice of selecting the point of entry for medicines administered e.g., either upstream or downstream of the stent portion 14. For instance, medicines, such as non-thrombogenic drugs, can be administered upstream of~the stent portion 14 where they would be most effective in the region of the stent portion 14.
, , - - : ::: , . -,: ~
- . . ~ - , .~ : . . :
, ~ , :- :
~6~8~
To remove the temporary stent 10, the stent portion 14 is first contracted from its expanded configuration to a reduced configuration. To do this, the first elongate member 28 is moved proximally relative to the second elongate member 32 thereby drawing down the diameter of the stent portion 14 to a size to facilit~te removal from the vascular system.
The wires of the stent portion 14 should smoothly peel from the vessel wall causing no or only minimal trauma.
It is nvt necessary that the stent portion 14 be drawn down entirely to its completely reduced size. It is sufficient that the stent portion 14 is drawn down sufficiently to disengage the inner walls of the -vascular region and to be of a size sufficiently small to traverse the vascular system out of the body. Then, after the stent portion 14 is in a reduced configuration it may be removed from the vascular system by drawing it out by means of the attarhed actuator portion 18.
The inner catheter 44 of the elongate member 14 has a geometry and is comprised of a material to provide ~or ~lexibility, tracking, axial compressive and tensile strength and rigidity for actuation of the stent portion 14. In a most preferred embodiment, the inner catheter 44 of the elongate member 14 is comprised o~ a thin~walled polyimide. Alternatively, the inner catheter 44 may be a polycarbonate, polyester or PET (high modulus polymer~ tube. Such materials provide for the desired pxoperties.
A lubricious coating may be utilized on the inner catheter 44. The lubricious coating may be a hydrophilic material, paralyene, teflon, or silicone.
Such a coating may be utilized on either the inner or .. ~ - .
, ~ :
the outer surfaces of the inner catheter 44 or both. A
lubri~ious coating on the inner surface of the inner catheter 44 facilitates over-the-wire movement of the temporary stent. A lubricious coating on the outer surface of the inner catheter 44 provides for low friction with the outer catheter 54 for good deployment and actuation of the stent portion 14.
The outer cathPter 54 of the Plongate member 14 should also have a geometry and should be comprised of a material to provide for flexibility, tracking, axial compressive and tensile strength and rigidity for actuation of the stent portion 14. In a most preferred embodiment, the outer catheter is made of polycarbonate. Alternatively, the outer catheter may be comprised of a thin-walled polyimide, polyester or PET (high modulus polymer) tubeO
A lubricious coating may also be utilized on the outer catheter 54. The lubricious coating may be a hydrophilic material, paralyene, teflon, or silicone.
such a coating may be utilized on either the inner or the outer surfaces of the outer catheter 54 or both. A
lubricious coating on the inner surface of the outer catheter 54 provides for low friction with the inner catheter 44 for good deployment and actuation of the stent portion~l4. A lubricious coating on the outer surface of the outer catheter 5~ facilitates positioning of the temporary stent in th~ patient's vascular system.
In an alternative embodiment of the present invention, the inner catheter 44 is comprised of a .021 X .028 inch polymeric tubing. The tubing used may be a blended Poly-Ethylene comprised of High Density Polyethylene (HDPE) and Low Density Poly-Ethylene 2~6~82 (LDPE). Alternatively, the inner cathet~r 44 may also be constructed of Poly-Propylene, ~PFE te~lon or TPX.
(TPX is a trade name for the Methyl Methylpentene Copolymer manufactured by Mitsui Plastics, Inc. and distributed from White Plains, NY). The use of TPX
enables the stent to be used for ultrasound imaging of the vessel that is being supported by the stent bacause the acoustical properties of this polymer match to that of water and blood.
lo Referring to the first elongate member 28, the inner tubular layer 56 may be constructed of the same combination of polymers described for the inner catheter 44. The inner tubular layer 56 may terminate 3 to 30 cm proximally from the proximal end 30 of the stent portion 14. This provides for the ability to reduce the section of the outer layer 58 by way of a drawing lor necking operation) on the outer layer 58.
The size for this inner tubular layer 56 of the first elongate member 28 is .033 X .039 inch.
The outer tubular layer 58 of the first elongate member 28 may also be constructed of blended HDPE-LDPE, or polypropylene. The dimensions of the outer tubular layer 58 of the embodiment may be .045 X
.053 inches in the proximal section of the first elongate member 28 extending from the manifold 24 at the proximal end to approximately 3 to 30 cm from the proximal portion 30 of the stent portion 14. From this point distally, the outer tubular layer 58 may be reduced to .039 X .045. This may be accomplished by a necking or drawing operation which is achieved by pulling th~ tube through a heated die and allowing the plastic to reflow.
: : ~ ' ' , ~ ', ' 2~8~82 The inner dimension o~ the outer tubular layer 58 as well as the distal necked region 60 i~
adjusted accordingly for a 3.0 or 3.5 mm stent as may be seen to accommodate the wire of greater thickness.
Since the outer diameter of the inner tubular layer 58 is .039 inches the placement of the braid on top of this layer, i.e. in the lumen 72, adds a factor of four times the wire thickness to the profile of the device prior to installation of the outer tubular layer 58.
It is thereEore apparent that the inner diameter of the outer tubular layer 58 should be adjusted to a minimum of .047 inches for the 3~0 mm and 3.5 mm versions. The tubing dimension may then be adjusted ~or the outer tubular layer to .055.
The stent portion 14 is comprised of a composite system that provides a consistent geometry during repeated expansions and contractions. In a most pref~rred embodiment, the stent portion has a geometry comprised of a uniform cylindrical middle portion with abrupt cone shaped geometries at the distal and proximal ends. This geometry minimizes constriction or impedance of the blood flow. The cone shaped regions at the distal and proximal ends have minimal lengths and preferably form an angle from the axial direction greater than 45 degrees. In a most preferred embodiment, the length of the stent portion is appxoximately 25 mm when in the expanded configuration.
In a most preferred embodiment, the stent portion is formed of a composite braid. The composite braid i~ formed of a resilient metal alloy wire coated with a polymeric coating. In the most preferred embodiment, the wire used for the composite braid is a heat treatable cobalt-chromium-nickel-molybdenum basQd alloy, such as Elgiloy or MP35N. In a most preerred embodiment, the Elgiloy wire used in the construction of the stent portion 14 is a round wire having a diameter of approximately 0.002 to 0.0025 inches. In one embodiment, the Elgiloy wire is treated to cause a metallurgical phase change so that the wire assumes a set shape to which it will have a tendency to resiliently resume. With Elgiloy wire, this phase change may be obtained by methods that are well known in the art and include steps o~ cold working and then heat treating the wire in the desired configuration to approximately 900 to 1000 degrees Fahrenheit. Other heat treatable alloys such as a stress relieved stainless steel could he utilized. Wire of other dimensions may also be used. Preferably, the Elgiloy wire is formed into a braid of a size corresponding to the radially expanded size. Then, the wire is heat treated with the braid of the stent portion in the expanded configuration thereby imparting the desired memory shape to the braid. Th n, the braid may be drawn down to a reduced size for positioning in the vascular system. In alternative embodiments, the diameter of the stant portion in its expanded configuration may be 2~5, 3.0, 3.5, 4.0 mm or other dimensions as desired. This heat treatment imparts high resiliency and a geometrical shape memory to the wire forming the braided composite stent portion.
In further embodiments, the braid may be treated in the reduced sixe or in an intermediate size between the reduced and expanded size. In such further embodiments, the stent will tend to resume the size in which it was treated. These alternative embodiments may be preferred in certain circumstances.
- . . ~ . , : :. : , . . .
20~8~8~
The pick count of the braid i5 a faator in the amount o~ treatment and the distance o~ axial travel associated with the braided wire that ~orms the stent portion. ~The pick count is the number of crossings down a single axial line of elements per inch . For purposes of this specification, the pick count may be determined at the braiding stage before the stent is traated, such as by heating). A smaller pick count provides for less travel which which in turn minimizes trauma to the vessel. In a preferred embodiment, a braid having a pick count of less than 16 is used. In a most preferred embodiment, a braid having a pick count of 12 is used.
In a most preferred embodiment, the braid of wires that comprise the stent portion is formed of fewer than 20 wire elements. In a preferred embodiment, the stent portion is formed of 8 wire elements. At the crossing locations of the wires, the wires preferably form an axially-directed angle of 90 degrees or less and more preferably form an acute, axially-dir cted angle. This provides the advantage of minimizing the amount of material used in the stent thereby enhancing perfusion therethrough.
As mentioned above, in a most preferred embodiment, the composite stent includes a coating on the wire braid that forms the stent portion. The coating material is preferably a polymeric material such as polyurethane, silicone, or other high modulus, high elongation polymers. In a most preferred embodiment, the coating is an aliphatic polyurethane.
The coating encapsulates and adheres to the crossing points and individual wire elements that form the braid, thus alIowing rotation of these crossing points : . ~ , : , : : . ~
20~8~82 ~ 25 -through elongation of the polymer, but preventing translation of the crossing points by adherences to the wire stands. The coating is prePerably applied after the braid has been appropriately treated in an expanded configuration to impart a resiliency and memory to the metal braid, as described above. The coating thereby further enhances the memory shape characteristics. The coating may be sprayed on or applied by other methods such as by dipping or by dispersion. In a preferred embodiment, the coating is approximately less than 0.002 inches in thichness and preferably less than 0.001 inches in thickness. The coating may be thicker in some areas such as proximate to wire crossings. In alternative embodiments, other means may be utilized to "tie together" wire crossovers to enhance braid integrity as well as to impart stabilized lifting and holding properties to the braid.
In the most preferred embodiment, the stent portion possesses both dynamic and static stability.
Dynamic stability allows the stent portion to lift an intimal vessel flap or vasoconstriction. Static stability allows the stent portion to maintain the vessel lumen by holding up a flap constriction or a vasoconstriction or vasospasm once the stent portion is in its expanded configuration. With the composite stent portion comprised of Elgiloy wire coated with an aliphatic urethane, these properties are provided with relatively few wire elements thereby allowing for a high level of blood perfusion through the stent. Also, ~0 with the composite stent, the overall dimensions of the stent can be minimizPd thereby facilitating tracking of the stent device to the desired vessel location.
Through the use of the composite stent with the wir~
. ~ .
2~8~82 braid of expanded geometry memory and the non-translatable wire crossings, the number of wires need to form the stent portion can be minimized while still provi~ing the necessary stability to the stent to maintain vessel patency for extended periods of time.
With a composite stent of the materials as described above, the stent can "lift" up to three 120 gram forces applied radially to a portion of the stent at 120 degree intervals around the location. A stent a~cording to this embodiment would therefore provide - for the ability to maintain the vessel open during most occurrences of vasoconstriction or vasospasm.
When devices are designed for use within the coronary arterial system size becomes a very significant factor. Each 1/lOOOth of an inch is significant both because of the primary concern which is restriction of flow, but also because of the added stiffness that results when a composite of tubular layers are sandwiched together to form the actuator member. For this reason, in one alternative embodiment, wire of rectangular cross section (herein referred to as flat wire) are utilized. One size of wire to make a 2.0 mm stent is .003 inches. For a 2.5 mm stent, wire of a size of .003 to ~0035 may be used.
For a 3.0 and 3.5 mm stent, wire of either .0035 or .0040 should ke used. From this, the advantage of using flat wire beGomes apparent. For each of the stent sizes, added thickness due to the braid is detailad below.
SIZE WIRE SIZE DIAMETRAL
2 . O . 0015 FhAT . 006 2 . 0 . 003 ROUND . 012 20~8~82 2.5 .0015 FhAT ~006 2.5 .003 ROUND .01 .0035 ROUND .014 3.0 ~002 FhAT .008 3.0 .0035 ROUND .014 .004 ROUND .016 3.5 .002 FLAT .008 3.5 .0035 ROUND .012 .004 ROUND .016 From the abovel the significance of the use of flat wire can be appreciated. It may be ssen that a large profile change results using flat wire as opposed to round wire. Additionally, the use of the larger flat wire results in devices that are considerably stiffer.
In this alternative embodiment, the braiding operation uses flat wire. In this embodiment, a 2.0 mm stent is constructed with a braid mesh network using stainless steel wire of rectangular cross section with a thickness of .001 inch X .004 inch. In this embodiment, for a 2.5 mm stent the wire used is stainless steel wire with a rectangular cross section of .0015 inches in thickness and .004 inch in width.
In this embodimentj the 3 mm stent is constructed with a stainless steel wire of rectangular cross section with .002 inch thickness and .004 inch width. A 3.5 mm stent is constructed with either a .002 inch thickness and.004 inch;width, or a .002 inch thickness and .005 inch to .007 inch width.
The wires that are used for the braid of the stent portion can be fragile due to their small size and care should be exercised in the manufacturing process. This is particularly true for the small~r , ,. :- .-.: - ~ .
2~8~g2 wires such as the .003 inch round or the .0008 to .0015 thickness flat wires.
In this embodiment, the wire used in each of the aforementioned braiding operations is 304 stainless steel in a spring temper. The specific wire used is the Hyten (T~) wire available from Fort Wayne Netals of Fort Wayne, Indiana. Additionally, any one or more or and in an embodiment 2, 3, or 4 of the 8 wires that comprise the braid may be made of an alloy of 92%
platinum and 8% tungsten for the purpose of providing radiopacity. These alloys may are commercially available from a number of sources, such as Sigmund Cohn Corp. of Mount Vernon, N.Y., or California Fine Wire of Grover City, California.
The braiding process of the present invention requires modification of a commercially available braiding machine to achieve the desired consistency and braid density. In this embodiment, for both the round and the flat wires, the braid pattern is composed of 8 wires. Braiding machines range in size from 16 carriers to 100 carriers. The braiding machine used for the manufacture of the stent described herein is a modified KoKobun SL~4-16 braider available from Wardwell Braiding Machine Co. of Rhode Island, NY.
This same company also manufacturers a series of hraiders under the New England Butt trade name. The braiders may be manufactured to accommodate 4, 6, 8, 10, 12, 16, or 24 bobbins in the machine groups d~fined as NE Butt #1, #2, or the B-11-8. These are all very small bench top versions that are used for small fibers or wire when fragile tensioning is required. The KoKobun is similar to the New England #2. The N E Butt B-9 which is a New England But~ #1 could conc~ivably be 2~68~82 modified to make a 6 or a 5 wire braid which would may also be used for this application.
Machine modifications include the removal of ~ of the 16 carriages, as well as the installation of ultra light tensioning springs on the braider carriages. Additionally the tent angle (i.e. the angle with which the wires approach the central core on which the braid is being installed) normally is free to float up and down as the braiding wire position and rate equilibrate on the central core. For the application of flat wire, the wire may tend to get caught on other wires which are being applied in the opposing direction. The wires then would get flipped over every few linear inches of braid therefore making the segment unusable or incorporatable within the catheter. This problem may be eliminated by providing an angled guide made of a low friction material such as teflon and containing the angle for which the desired tent angle should be guided.
The size and density of the stent is controlled by three variables: the size of the central core to which the braid is being applied; the rate of advancement of the central core through the braid region; and the angular velocity of the braiding carriages. These variables relative to each other determine the "pick" (number of wire group intersections per inch) density of the braid pattern~
These variables also determine the size of the stent that will be manufactured.
In this embodiment, a 2.0 mm stent is made on a central core with a size of .050 inches and a density of 10 per inch. When removed from the core the stent will spring from the I.D. of ~055 to 2.0 mm an~ have a 2~8~82 pick density of approximately of 7 to 15 per inch or approximately .14 to .07 inches between groups or 3.6 mm to 1.8 mm. The de~ree for which the stent expands when removed from the core depends on the pick density during the braiding operation.
The table below outlines the expanded pick densities for the individual stent configurations. The braiding machine us~d must be modified so that the take up velocity of the central core and the radial velocity may be adjusted very precisely to achieve the exact density required. Due to the addition of the guide, as explained above, the density of the braid will not be allowed to assume its own pattern density by climbing up and down the central core, but instead will assume 15 the required density.
size core size pic distance when expanded 2.0 .050 1.8 to 3.6 mm 2.5 .055 1.8 to 3.6 mm 3.0 .062 1.8 to 3.6 mm 03.5 .068 1.~ to 3.6 mm From the table, the desired density in this embodiment is obtained by placing the bridges 1.8 to 3.6 mm apart. Rs mentioned above and unlike a dilation device, an feature of the temporary stent is that it is highly perfusable. This is accomplished in part by minimizing the density of metal within the vessel which may restrict the blood flow both though the ends of the stent and also radially from the sides of the stent. This is important because frequently side branches to the blood vessel are contained in the stent region and flow must exit the stent to keep these side branches : ~ : ' .': .:
.
2 ~ 8 2 perfused. The area or size of the stent should be minimized to maximize perfusion while maintaining sufficient structural support for a flap or other damaged part of the vessel.
The stent portion should not only be perfusable to allow blood flow therethrough, but should also minimize surfaces upon which a thrombus might form. The vascular system is very active with respect to clot formation once a vessel has been damaged or subjected to other trauma such as during an angioplasty~ Any device that is installed for more than a faw minutes is susceptible to clot formation. Because in some embodiments, the temporary stent may be used ~or up to several ~ays, it should also provide for minimization of clot ~ormation.
One way the temporary stent minimizes clot formation is by preparation of the surfaces of the wires of the stent portion. The wires of the braid in this embodiment are made of rectangular wires braided into a 4, or 8 wire braid and rectangular wire may, by reason of the manufacturing processes, have edges that are very and/or sharp. The wire is made by initially drawing it throuyh a die in order to form the specific size that is desired. During this process the temper of the spring may be modified by the cold work that is being induced into the wire from the forceful shaping of the wire. In the case of the HyTen 304 SS wire, the spring 3Q tempers are being achieved with pressures which are substantially greater than 300,000 psi. This spring temper is very desirable from the standpoint of imparting desirable properties to the stent.
~. , ~ a ~ 2 Specifically, the stent must be resilient to return from its initial contracted configuration to the full expanded state with only a minimal application o~ external force. The temper is relevant to the fabrication process and ultimately to the product performance.
The edges formed on the flat wire are rounded off. The method used to radius the corners of the flat wire is electropolishing which removes edges or protrusions of the material and passivates the metal without altering the bulk properties of the metal. The metal is left in a passive state by the electropolishing process and the metal is also highly resistant to corrosion.
The electropolishing operation requires the use of an electrolytic fluid. This fluid must dissolve the products ~formed on the work piece which in this case is the metal stent surface) by electro-chemical action. High current densities of 1000-5000 amps per square inch are maintained between the workpiece and a cathoda. A DC power supply is used to provide the required power. The rate of removal is reyulated by the current flow through the work piece. Corners or asperities extending from the surface of the work piece have a greater projected surface area/volume ratio than does the flat area. For this reason, material is removed from such regions at an accelerated rate.
Further, this operation is ideal for smoothing the flat wire in the ~tent region and radiusing the corners which other wire would exhibit sufficient sharpness to potentially scrape the endothelial cells from the inside of the vessel thus promoting - : , :: :~ .: :-: : . : , :. : , : : , 2~8~8~
thrombus. After electropolishing, a flat wire 79 may possess a rounded cornered cross sectional profile, as depicted in Figure 10.
The electropolishing operation may be performed as follows. The electropolishing solution should be selected which meets the operational requirements. An acidic solution should be selected which is compatible with the electro-chemical characteristics such that material may be removed without the production of carbides or other metal impurities on the surface which will result in corrosion. A direct current (DC) power supply is provided to provide the electromotive potential required to force the electrochemical sacrifice of metal from the surface. The positive (~) terminal (the anode) is attached to the workpiece, and the negative terminal is attached to a non-corrosive negative (-) terminal piece (the cathode).
The stainless steel wire requires a voltage of approximately 5 volts to perform the polishing vperation. This voltage is dep~ndent on the electropolishing solution being used as the electrolyte. The solution being used in this embodiment is a solution of phosphoric acid, citric acid, deionized water, and ethyl alcohol. The operation is performPd at an elevated temperature in order to increase the rate of metal removal and provide for the smoothest possible surface. Other electrolytes are available additionally that are effective on the stainless steel. These solutions are frequently combinations of alcohol~ multiple acids, and water. Sulfuric acid based solutions are frequently used in electropolishing of stainless :, ~. , -. :
-` 20~3~82 steel. If other metals are used in whole or in part in the braid, e.g. platinum or tungsten, in order to provide for radiopacity, modifications to the method may be appropriate. Electropolishing solutions used on the platinum-tungsten material used on the rectangular wire used in the braid may be polished using a HF acid solution in the same manner as described above, or may be mechanically radiused prior to incorporation in the braid by winding the wire from spool to spool and passing over a sequence of polishing wheels. This may be preferred to avoid dealing with HF acid. Many of the other metals which alternatively will provide opacity under X-ray also are quite noble and require HF acid for polishing. The mechanical polishing method is preferable for these metals.
The ease of electropolishing the stainless steel and the smooth-burr free surface that is provided makes this the method over mechanical removal. It must be understood that mechanical removal is also possible and relatively easy with the stainless steel.
The stainless steel that is in the austenite alloys provides a self-repairing oxide film which prevents corrosion. Passivity may be diminished or lost by any process in which a localized oxygen withdrawal occurs by any means.
Heating or chemical reactions are capable of relieving this oxygen. The passive state may be restored to the material by exposing th~ material to an oxidizing environment such as nitric acid. The passivation state may be altered during the electropolishing operation if the parameters are not ~ - 34 -2 ~ 8 2 closely controlled. The voltage driving the chemical reaction will affect the passive state of the remaining surface. In the case of the process utilizing the phosphoric acid solution the voltage and temperature at which the process is operated at is 80 degrees celsius and 5 +/ .25 volts. The specific solution composition is 757.6 c~/liter phosphoric acid, 181.8 cc/liter de-ionized water, 60.6 cctliter denatured alcohol, and 303.0 grams/liter citric acid.
In addition to the electropolishing step described above, clot formation can further be minimized by the application of one or more anti-thrombogenic coatings. In this embodiment, the braided wires are coated in two layers with a silicone oil solution. The surface is treated twice to achieve complete surface coveraga. Since the engagement of the braided stent s~ction results in a relative movement of the individual wires with 2Q respect to each other, the stent region is coated in both an expanded and contracted configuration. The coating used in this embodiment is Dow Corning (R) MDX4-4159 silicone fluid. The coating may be applied in accordance with the instructions in Dow Corning Bulletin 51-599 (July 1982) for the MDX4 4159 silicone fluid which is incorporated herein by reference.
Although a braid is a presently preferred construction for the perfusable stent portion 14, oth2r alternative embodiments may include a plurality of parallel wires forming a hollow cylindrical tube each wire substantially parallel to the axis of the hollow cylindrical tube. In this - ; ., : :.. :
- .- :, : :: ,: : .: ~: -., , :
2~6~5~2 alternative construction, at the ends of the elongate hollow tube formed by the plurality of wires, each wire would include an oblique bend so that each wire could be connected to the actuator portion which is aligned with the axis of the hollow tube formed by the wires. Relative displacement between the ends of the wires would cause the oblique angles at the end of each wire to change thereby increasing or decreasing the diameter of the hollow tube to enable placement or removal of the stent from the vascular region of the patient's body. Other alternative constructions for the stent portion may also be provided.
In accordance with the present embodiment, it is presently preferred to utilize a temporary stent of a specific and selected expanded size suitable for the region of the vascular system in which it is intended to be installed. Accordingly, it is presently intended with this embodiment to utilize dif~erent sizes of stents where different expanded sizes are needed. Alternatively, where th~re is a need to apply a temporary stent in a small size vessel, instead of using a small size temporary stent, it is possible to utilize a large size temporary stent (i.e. one that is expandable to a large diameter) but to only expand it partially to an intermediate expanded diameter size. This could be accomplished by fixing the proximal ends of the actuator portion 18 and the inner elongate member 26 at an intermediate position between where the catheter is fully compresssd and where it is fully expanded.
, . . . .
`` 2 ~ 8 2 These dimensions provided above are intended as approximate and other sizes and dimensions may be selected and designed in accordance with the teachings of the present invention.
In a most preferred embodiment, the temporary stent is operated by means of a manifold assembly 220, as depicted in Figures 12 and 13.
Referring to Figure 12, the manifold assembly 220 connects to the proximal end of the elongate member 14. The man.ifold assembly 220 includes a body portion 222 made of polycarbonate. The body portion 222 includes a reservoir 224 located internally thereto. An insert 226 is located in the body portion 222 and forms a distal end wall of the reservoir 224. A first 0-ring 228 forms a seal between the insert 228 and the body portion 222.
The proximal portion of ~he outer catheter 54 communicates with the reservoir 224 via a distal opening 230 of the body portion 222. A strain relief member 232 fits over the proximal end of the outer catheter 54 at the location where it enters the distal opening 230 of the body portion 222. The strain relief member 232 is preferably conically shaped and made of pellethaneO The proximal end of the outer catheter 54 terminates at the reservoir 22~.
The body portion 222 also includes a port 234 communicating with the reservoir via a luer connection 236. Fluids such as medicines can be supplied via the port 234. Fluids supplied via the port 234 are thereby transported within the lumen of the outer catheter 54 in the annular region between -.: . . , .: . . : . ....
2~68~2 the outer catheter 54 and the inner catheter 44 and discharged into the vessel at the distal termination of the outer catheter 54 at the proximal end o~ the stent portion 14.
A hypotube 238 is fixed to the outer diametsr of the inner catheter 44. The hypotube 238 is preferably made of stainless steel. The proximal end of the hypotube 238 extends through an opening 240 through the insert 226. A second 0-ring 242 fits between the hypotube 238 and the insert 226 to form a fluid tight seal.
The proximal end of the hypotube 238 terminates in an actuator member 244. Referring to Figure 13, the actuator member 244 includes wings 246 that fit in corresponding grooves 248 of the body portion 222 so that the actuator member 244 can move longitudinally relative to the body portion 222 but not rotationally. The wings 246 also provide for structural support between the body portion 222 and the actuator member 244. The actuator member 244 includes a luer connection 250 on a distal end that communicates with the lumen of the inner catheter 44 via the lumen of the hypotube 238. In a preferred embodiment, the lumen of the inner catheter 44 is used for a guide wire so that the temporary stent can be positioned in the vascular system by means of an over-the-wire procedure. (In alternative embodiments, the temporary stent may use a fixed wire or a rapid exchange construction for positioning in the patient's vessel).
The actuator member 244 i5 sized and adapted for limited movement longitudinally in the body portion 222. Referring again to Figure 12, a 2 0 6 8 ~ 8 2 locking member 252, which in a pre~erred embodiment is a nut comprised of mating pieces of polycarbonate, f its over the proximal end of the body portion 222. The nut 252 includes a detente 5 that engages one of the wings 246 of the actuator member 244 in order to lock it in either a fully extended or a fully retracted position with respect to the body portion 222. When the actuator member 244 is ~ully retracted proximally with respect to the body portion 222, this corresponds to the at-rest configuration of the stent portion in which the stent assumes its expanded configuration. When the actuator member 244 is fully extended distally with respect to the body portion 222, this corresponds to the contracted configuration of the stent such as when the stent is being positioned in or removed from the vessel.
~ eferring to Figure 6, there is depicted the distal end of another embodiment of the present 20 invention~ The proximal end (not shown) could function similarly as in the first described embodiment. In this embodiment, a temporary stent 80 has a stent portion 82 and a actuator portion 84.
The stent portion 82 is connected to the actuator portion 84 at a proximal end 86 of the stent portion 82. An inner elongate member 88 extPnds throuqh the stent portion 82 and th~ actuator portion 84. As in the previous embodiment the inner elongate member 88 is connected to a distal end 90 of the stent po.rtion 82. Also, as in the previous embodiment, the inner elongate member 88 may be moved relative to the actuator portion 84 to cause expansion and contraction of the stent portion 82~
, :: , ,.. :.... . .. .
: :: . , ., ., :
,. : : : ~: , ,,: . ~, ;. ~: : - : ; . ~:
In this embodiment, the inner elonga~e member 88 further includes a guidewire tip 92 that extends distally from the distal end 90 of the stent portion 82. The guide wire tip 92 is flexible and formable and includes a rounded portion 94. The guidewire tip 92 facilitates positioning the temporary stent 80 in the vascular system. In Figure 4, the guidewire tip 92 is depicted having a curvature although it should be understood that the guidewire would normally be provided in a straightened position and that the curvature may be imparted by a physician prior to insertion into the vascular system of the patient in order to facilitate positioning of the stent. The guidewire tip 92 may assume a curvature such as depicted during its positioniny in a tortuous vessel path.
In this embodiment, the temporary stent ~0 may be positioned by means of the guidewire tip 92 instead of over a separate guidewire that is located the inside an inner catheter (e.g. lumen 5Q of inner catheter 44 in the first embodiment).
Referring to Figures 7 and 8, there is depicted another embodiment of the present invention. In Figures 7 and 8, a temporary stent 100 includes a stent portion 102 and a actuator portion 104 connected to each other at a proximal end 106 of the stent portion 10~. In this embodiment, a distal end 10~ of the stent portion 102 includes a cylindrical shaft 110 having a cylindrical opening 11~ therethrough. The cylindrical shaft 110 includes at least one bearing surface 116 thereupon. An inner elongate number 118 is located in the hollow tube of the formed by the ~ , . . , ; , . - . . ,. :, . .. ..
.: : : ; .. , .. : , ~ - ... .
2~8~82 stent portion 102 and extends proximally as in the previous embodiments. Unlike the previous embodiments, the inner elongate member 118 is not fixed to stent portion 102. Instead, the inner elongate portion 118 has a narrow distal portion 120 positioned to be slidingly received in the opening 112 of the shaft 110. A first shoulder 122 on the inner elongate member 118 is located to bear upon the surface 116 when the inner elongate member 118 is moved distally. The inner elongate member 118 also includes a second shoulder 126 formed distally of the narrow distal section 120. The second shoulder 126 is located to bear upon another surface 128 of the inner elongate member 118. Proximal movement of the inner elongate member 118 causes the shoulder 126 to bear upon the surface 128 causing expansion of the stent portion 102. As shown in Figure 8, the second shoulder 126 may form part of a guide wire tip 130. ~owever, other configurations for the tip are also suitable. With the embodiment of the invention depicted in Figures 7 and 8, limited axial movement of the inner elongate member 118 is provided which may be suitable and desirable Eor positioning and removal of the removable stent.
As shown in Figures 7 and 8, tha surfaces 116 and 128 and the shoulders 122 and 126 may be formed to prevent removal of the inner elongate member 118 from the actuator portion 104 and stent portion 102 although removability may be provided by alignment of the shoulders 106 with the bearing surface 128.
As in the previously described embodiment, with this embodiment a separate guide wire is not required to .. . .
2~8~82 position the temporary stent inside the vascular system.
As described above, because the temporary stent will be left in the vascular system for a period of time, the temporary stent should avoid or minimize clotting or platelet aggregation in and around the stent portion. Also, it is advantageous to reduce the tendency of the stent to permanently adhere to the inner surface of the vascular walls in order to facilitate removal of the stent. This may be accomplished by providing or imparting to the temporary stent properties that will minimize these tendencies.
In one alternative embodiment, the stent portion includes a coating of a slow release polymer having anti-thrombogenic properties. Such polymers include drugs such as urokinase, heparin, antithrombin III or other thrombon-resistive agents.
The polymer used~may be polyethylene or a polyolefin.~
The natural surface charge that is present intrinsically on a material is considered to be a factor in the chain of successive events that results in the formation of mural thrombus on an artificial surface. Although, the blood coagulation cascade is complex and not fully understood, it is accepted that on an artificial surface, characteristics such as low surface energy ~i.e.
hydrophobic), and the electro-negativity of the surface af~ect the initial events that are important to subsaquent rPactions or svents that result in the formation of thrombus. For this reason, in this embodiment, the surface is coated with a silicone 20~o~82 oil solution which is of a low sur~ace energy.
Other alternative coatings that will provide relative thromboresistance include teflon, and pyrolytic carbon. While pyrolytic carbon has a relatively high surface energy of approximately 50 dyne/cm which is generally not considered thromboresistant, upon exposure to blood it has been observed to present a change to about 30 dyne/cm.
This is considered to be thromboresistant and is ~0 thus a widely used material in coating of metal heart valves. The relative success of the stent in placement in vivo is dependent upon the ability to manipulate the surface characteristics to "tune" the device to the requirements that are present but not fully understood in the blood chemistry reactions.
Other methods may be used to provide this property. For examplP, the surface of the stent portion may effectively be charged and polarized to prevent the sequence of events that results in clot formation. By installing an external ground plane to the patient and placing a lead to the metal surface, the braid may be energized such that it is essentially an insulated capacitor which will provide the surface charge of desired magnitude, and polarity. The voltage level supplied to the wire is effectively additive to the natural negativity of the surface. The net potential may be effectively adjusted to a zero, positive, or negative charge.
R~ferring to Figure 9, a charge is imparted to the stent portion. The DC power supply 150 is located outside the vascular system. Only a small current is necessary (for example, less than 50 microamps).
This could be provided by a small battery such as a ~068~82 watch battery. This would be sufficient to impart a charge to the stent portion to minimize the tendency for clotting materials to form on the stent portion.
The polarity may be selected based upon consider-ation of factors, such as material, coating,medication, etc. A lead 152 is connected to the stent portion of the temporary stent and the other lead 154 i~ connected to the body 156 of the patient. As described above, the proximal end of the stainless steel braid comprising the stent portion could extend all the way to the proximal end of the outer catheter to form part of, or to connect to, lead 152. The braid may provide a pathway proximally to the manifold which provides an electrically conductive pathway so that a surface charge may be placed which in effect overrides the natural electro-negative characteristics of the stainless steel metal surface from which the braid ~ is formed. Alternatively, the wires that make up the stent portion~may connect to a lead at a point proximally from the proximal end of the stent portion and the lead could extend proximally.
Additionally by providing a waveform polarizing ~unction, the stent surface may be polarized with a time varying potential. The application of a high frequency current in the kilohert~ to the megahertz range is a procedure that has been tested for healing of wounds. The construction of the stent portion is designed to have a periodic surface contact with the wounded vessel~ and a network for applying desired voltage, and polarities and frequencies to an Lntimate contact with the wounded vessel. The device may be - - : : : , . ~ : . : ,:: : , 2~8~2 constructed to apply current to the stent of O ko 20 micro amp to the surface when an uncoated surface is used or whPn a noble coating such as gold or platinum is applied. Gold may be applied by standard vapor deposition process known as sputter coating, or by an electro-chemical plating process.
Platinum is normally electro-plated.
Anoth~r method for imparting a charge to the stent portion is by means of an RF signal. By this method, the proximal end of the stent portion will be connected to a RF source.
It is intended that the foregoing detailed description be regarded as illustrative rather than limiting and that it is understood that the following claims including all equivalents are intended to define the scope of the invention.
.. .- i ; ,. ~
: ~ . . , : : ~ . :
. . :,. . : .
Claims (42)
1. A removable stent for temporarily supporting a region of a vessel in a body comprising:
a composite stent portion comprised of:
an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough, and further in which said composite stent portion is comprised of:
a plurality of wires forming an elongate hollow tubular braid, and a coating applied to said tubular braid to limit relative translation of one of said plurality of wires with respect to another of said plurality of wires at a location in said braid at which the one of said plurality of wires crosses the other of said plurality of wires; and an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size.
a composite stent portion comprised of:
an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough, and further in which said composite stent portion is comprised of:
a plurality of wires forming an elongate hollow tubular braid, and a coating applied to said tubular braid to limit relative translation of one of said plurality of wires with respect to another of said plurality of wires at a location in said braid at which the one of said plurality of wires crosses the other of said plurality of wires; and an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size.
2. A removable stent for temporarily supporting a region of a vessel in a body comprising:
a stent portion comprised of:
an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough; and an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size;
and further in which said stent portion comprises expanded a resilient material having a memory to assume said size.
a stent portion comprised of:
an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough; and an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size;
and further in which said stent portion comprises expanded a resilient material having a memory to assume said size.
3. The temporary stent of Claim 2 in which said stent portion is comprised of a plurality of wound wires of a material treatable to resume a desired configuration.
4. The temporary stent of Claim 2 in which said stent portion is comprised of a plurality of wound wires of a treatable cobalt chromium-nickel-molybdenum based alloy.
5. The temporary stent of Claim 2 in which said stent portion is comprised of a plurality of wound wires selected from a group consisting of: elgiloy and MP35N.
47a
47a
6. The temporary stent of Claim 2 in which said stent portion comprises a plurality of wound wires of a metal formed to resiliently return to a configuration conforming to said expanded size.
7. The temporary stent of Claim 1 in which said stent portion is comprised of a first set of wires helically wound in a first direction and a second set of wires helically wound in a second direction such that when said vessel supporting portion is in said expanded size, the wires of said first set form acute angles with the wires of said second set.
8. The temporary stent of Claim 1 in which said stent portion is comprised of a plurality of wound wires forming a braid having a pick count of less than 16.
9. The temporary stent of Claim 1 in which said stent portion is comprised of a plurality of wound wires forming a braid having a pick count of 12.
10. The temporary stent of Claim 1 in which said stent portion is comprised of a plurality of wound wires of a diameter of approximately 0.002 to 0.0025 inches.
11. The stent of Claim 1 in which said composite stent portion is comprised of:
a plurality of helically wound wires forming an elongate hollow tube, and a coating applied to the plurality of helically wound wires.
a plurality of helically wound wires forming an elongate hollow tube, and a coating applied to the plurality of helically wound wires.
12. The stent of Claim 11 in which said coating is formed of a high modulus, high elongation polymeric material.
13. The temporary stent of Claim 11 in which said polymeric material is selected from a group consisting of: polyurethane and silicone.
14. The temporary stent of Claim 12 in which said polymeric coating is an aliphatic polyurethane.
15. The temporary stent of Claim 11 in which said coating encapsulates and adheres to crossing points of said plurality of helically wound wires thereby allowing relative rotation of wires at said crossing points but preventing translation of the wires at said crossing points.
16. The temporary stent of Claim 11 in which said coating is preferably applied to said plurality of helically wound wires after said plurality of wires has been treated to resume an expended configuration.
17. The temporary stent of Claim 11 in which said coating is less than approximately 0.002 inches in thickness.
18. A removable stent for temporarily supporting a region of a vessel in a body comprising:
a stent portion comprised of:
an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough; and an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size, said actuator portion comprising:
a first elongate member comprising an elongate catheter tube connected to said proximal end of said stent portion, and a second elongate member slidably disposed in a lumen of said first elongate member and extending to and operable to move said distal end of said stent portion with respect to said proximal end of said stent portion;
a first marker connected at approximately the distal end of said stent portion;
a second marker connected at approximately the proximal end of said stent portion, whereby the length of said stent portion can be determined by observation of said first and said second markers.
a stent portion comprised of:
an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough; and an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size, said actuator portion comprising:
a first elongate member comprising an elongate catheter tube connected to said proximal end of said stent portion, and a second elongate member slidably disposed in a lumen of said first elongate member and extending to and operable to move said distal end of said stent portion with respect to said proximal end of said stent portion;
a first marker connected at approximately the distal end of said stent portion;
a second marker connected at approximately the proximal end of said stent portion, whereby the length of said stent portion can be determined by observation of said first and said second markers.
19. The temporary stent of Claim 18 further including:
a third marker connected to said second elongate member in a portion corresponding to the stent portion, whereby the relative positions of said first and second elongate members and thereby the size of said vessel supporting portion can be determined by observation of the position of said third marker relative to said first and second markers.
a third marker connected to said second elongate member in a portion corresponding to the stent portion, whereby the relative positions of said first and second elongate members and thereby the size of said vessel supporting portion can be determined by observation of the position of said third marker relative to said first and second markers.
20. The temporary stent of Claim 19 in which said third marker is connected to said second elongate member at a location such that when said vessel supporting portion is in said expanded size said third marker is proximate to said second marker.
21. The temporary stent of Claim 18 in which said markers are made of platinum with 10%
iridium.
iridium.
22. A removable stent for temporarily supporting a region of a vessel in a body comprising:
a composite stent portion comprised of:
an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough; and an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size, said actuator portion comprising:
a first elongate member comprising an elongate catheter tube connected to said proximal end of said stent portion, a second elongate member slidably disposed in a lumen of said first elongate member and extending to and operable to move said distal end of said stent portion with respect to said proximal end of said stent portion, and a lubricious coating located between said second elongate member and said first elongate member.
a composite stent portion comprised of:
an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough; and an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size, said actuator portion comprising:
a first elongate member comprising an elongate catheter tube connected to said proximal end of said stent portion, a second elongate member slidably disposed in a lumen of said first elongate member and extending to and operable to move said distal end of said stent portion with respect to said proximal end of said stent portion, and a lubricious coating located between said second elongate member and said first elongate member.
23. The temporary stent of Claim 22 in which said second elongate member further includes said lubricious coating on at least one surface thereof.
24. The temporary stent of Claim 23 in which said lubricious coating is located on an inner surface of said second elongate member.
25. The temporary stent of Claim 23 in which said lubricious coating is located on an outer surface of said second elongate member.
26. The temporary stent of Claim 23 in which said lubricious coating is selected from a group consisting of:
a hydrophilic coating, paralyene, teflon, and silicone.
a hydrophilic coating, paralyene, teflon, and silicone.
27. The temporary stent of Claim 22 in which said first elongate member further includes said lubricious coating on at least one surface thereof.
28. The temporary stent of Claim 27 in which said lubricious coating is located on an inner surface of said first elongate member.
29. The temporary stent of Claim 27 in which said lubricious coating is located on an outer surface of said first elongate member.
30. The temporary stent of Claim 27 in which said lubricious coating is selected from a group consisting of:
a hydrophilic coating, paralyene, teflon, and silicone.
a hydrophilic coating, paralyene, teflon, and silicone.
31. A method of stabilizing a patient's vessel during an occurrence or during a time when there is the potential for an occurrence of a restriction to blood flow through the vessel from a vasoconstriction, vasospasm, or similar condition at a location in the vessel, comprising the steps of:
positioning a temporary stent into the patient's vessel with a vessel supporting portion of the temporary stent in the vessel at the location and an actuator portion of the temporary stent having a distal portion connected to the vessel supporting portion and a proximal portion extending out of the patient's vessel;
manipulating the vessel supporting portion from the proximal portion of the actuator portion to cause the vessel supporting portion to change from a reduced size suitable for positioning of the temporary stent in the patient's vessel to an expanded size suitable for supporting the patient's vessel during an occurrence or during a time when there is the potential for an occurrence of a restriction to blood flow through the vessel from a vasoconstriction, vasospasm, or similar condition;
maintaining said vessel supporting portion in said expanded size while permitting blood perfusion through distal and proximal ends of the vessel supporting portion;
manipulating the vessel supporting portion from the proximal portion of the actuator portion to cause the vessel supporting portion to change from said expanded size to said a reduced size;
withdrawing the temporary stent after the condition or potential of a condition of a vasoconstriction, vasospasm, or similar condition has passed.
positioning a temporary stent into the patient's vessel with a vessel supporting portion of the temporary stent in the vessel at the location and an actuator portion of the temporary stent having a distal portion connected to the vessel supporting portion and a proximal portion extending out of the patient's vessel;
manipulating the vessel supporting portion from the proximal portion of the actuator portion to cause the vessel supporting portion to change from a reduced size suitable for positioning of the temporary stent in the patient's vessel to an expanded size suitable for supporting the patient's vessel during an occurrence or during a time when there is the potential for an occurrence of a restriction to blood flow through the vessel from a vasoconstriction, vasospasm, or similar condition;
maintaining said vessel supporting portion in said expanded size while permitting blood perfusion through distal and proximal ends of the vessel supporting portion;
manipulating the vessel supporting portion from the proximal portion of the actuator portion to cause the vessel supporting portion to change from said expanded size to said a reduced size;
withdrawing the temporary stent after the condition or potential of a condition of a vasoconstriction, vasospasm, or similar condition has passed.
32. The method of Claim 31 further comprising the step of:
during at least a portion of said vessel maintaining step, administering medicines from the proximal end of the actuator portion to a proximal portion of the vessel supporting portion via a lumen of an outer catheter member of the actuator portion.
during at least a portion of said vessel maintaining step, administering medicines from the proximal end of the actuator portion to a proximal portion of the vessel supporting portion via a lumen of an outer catheter member of the actuator portion.
33. The method of Claim 32 in which the positioning step further comprises:
maintaining an outer catheter connected to a proximal end of the vessel supporting portion in tension with respect to an inner catheter located internally to said outer catheter and connected to a distal end of the vessel supporting portion to maintain said vessel supporting portion in the reduced size as the vessel supporting portion is advanced through the patient's vascular system; and in which the manipulating step further comprises:
reducing the tension maintained on the outer catheter so that said vessel supporting portion resumes an expanded size.
maintaining an outer catheter connected to a proximal end of the vessel supporting portion in tension with respect to an inner catheter located internally to said outer catheter and connected to a distal end of the vessel supporting portion to maintain said vessel supporting portion in the reduced size as the vessel supporting portion is advanced through the patient's vascular system; and in which the manipulating step further comprises:
reducing the tension maintained on the outer catheter so that said vessel supporting portion resumes an expanded size.
34. A method of manufacturing a temporary stent comprising the steps of:
providing an elongate braid of treatable resilient metal wire stands in a size corresponding to a desired expanded size; and treating said braid while in the expanded size to provide the braid with a size configuration to which said braid will tend to resume.
providing an elongate braid of treatable resilient metal wire stands in a size corresponding to a desired expanded size; and treating said braid while in the expanded size to provide the braid with a size configuration to which said braid will tend to resume.
35. The method of Claim 34 in which said treating step further comprises:
coating the braid while in an expanded size with a polymeric material.
coating the braid while in an expanded size with a polymeric material.
36. The method of Claim 35 in which said coating step further comprises:
coating by at least one of spraying, dipping and dispersion.
coating by at least one of spraying, dipping and dispersion.
37. The method of Claim 35 in which said coating step further comprises:
coating the braid while in an expanded size with a aliphatic polyurethane.
coating the braid while in an expanded size with a aliphatic polyurethane.
38. The method of Claim 35 in which said coating step further comprises:
coating with a layer of polymeric material to a thickness of approximately less than 0.002 inches.
coating with a layer of polymeric material to a thickness of approximately less than 0.002 inches.
39. A method of manufacturing a temporary stent comprising the steps of:
providing an elongate braid of metal wire stands;
positioning the braid with a proximal end thereof on a first catheter member and a distal end thereof on a second catheter member; and winding coils around the proximal and distal ends of the braid to secure the braid to the first and second catheter members.
providing an elongate braid of metal wire stands;
positioning the braid with a proximal end thereof on a first catheter member and a distal end thereof on a second catheter member; and winding coils around the proximal and distal ends of the braid to secure the braid to the first and second catheter members.
40. The method of Claim 39 further comprising:
securing the wound coils by brazing.
securing the wound coils by brazing.
41. A removable stent for temporarily supporting a region of a vessel in a body comprising:
(a) a stent portion comprised of:
(i) an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and (ii) perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough, and further in which said stent portion is comprised of:
a plurality of wires forming an elongate hollow tubular braid, and further in which relative translation of one of said plurality of wires with respect to another of said plurality of wires at locations in said braid at which one of said plurality of wires crosses another of said plurality of wires is limited;
and (b) an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size.
(a) a stent portion comprised of:
(i) an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and (ii) perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough, and further in which said stent portion is comprised of:
a plurality of wires forming an elongate hollow tubular braid, and further in which relative translation of one of said plurality of wires with respect to another of said plurality of wires at locations in said braid at which one of said plurality of wires crosses another of said plurality of wires is limited;
and (b) an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said support portion into said reduced size and said expanded size.
42. A removable stent for temporarily supporting a region of a vessel in a body comprising:
(a) a stent portion comprised of:
(i) an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and (ii) perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough, and further in which said stent portion is comprised of:
a plurality of wires forming an elongate hollow tubular braid having sufficient structural strength for supporting three radially compressive forces on the order of 120 grams in order to support the region of the vessel; and (b) an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said supporting portion into said reduced size and said expanded size.
(a) a stent portion comprised of:
(i) an elongate perfusable vessel supporting portion adapted to be configurable between a reduced size for placement in the vessel and removal therefrom and an expanded size for structurally supporting the vessel in the region; and (ii) perfusable end portions connected to and forming ends of said vessel supporting portion and adapted to allow fluid flow therethrough, and further in which said stent portion is comprised of:
a plurality of wires forming an elongate hollow tubular braid having sufficient structural strength for supporting three radially compressive forces on the order of 120 grams in order to support the region of the vessel; and (b) an actuator portion having a proximal end extending out of the body and a distal end connected to said stent portion and operable by manipulation at said proximal end to configure said supporting portion into said reduced size and said expanded size.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/715,164 | 1991-06-14 | ||
US07/715,164 US5449372A (en) | 1990-10-09 | 1991-06-14 | Temporary stent and methods for use and manufacture |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2068582A1 true CA2068582A1 (en) | 1992-12-15 |
Family
ID=24872917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002068582A Abandoned CA2068582A1 (en) | 1991-06-14 | 1992-05-13 | Temporary stent and methods for use and manufacture |
Country Status (4)
Country | Link |
---|---|
US (1) | US5449372A (en) |
EP (1) | EP0518704A1 (en) |
JP (1) | JPH05200048A (en) |
CA (1) | CA2068582A1 (en) |
Families Citing this family (411)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE41029E1 (en) | 1990-03-13 | 2009-12-01 | The Regents Of The University Of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
USRE42625E1 (en) | 1990-03-13 | 2011-08-16 | The Regents Of The University Of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US6083220A (en) | 1990-03-13 | 2000-07-04 | The Regents Of The University Of California | Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas |
US7208013B1 (en) | 1990-06-28 | 2007-04-24 | Bonutti Ip, Llc | Composite surgical devices |
US6464713B2 (en) * | 1990-06-28 | 2002-10-15 | Peter M. Bonutti | Body tissue fastening |
ATE149325T1 (en) * | 1992-10-12 | 1997-03-15 | Schneider Europ Ag | CATHETER WITH A VESSEL SUPPORT |
CA2157936C (en) * | 1993-03-11 | 2004-11-02 | Gregory Pinchasik | Stent |
US5354310A (en) * | 1993-03-22 | 1994-10-11 | Cordis Corporation | Expandable temporary graft |
BE1006819A7 (en) * | 1993-03-24 | 1994-12-13 | Dsb Nv | Polyurethane coated prostheses (stents) FOR THE TREATMENT OF VESSEL CHOKES. |
IT1276342B1 (en) * | 1993-06-04 | 1997-10-30 | Ist Naz Stud Cura Dei Tumori | METAL STENT COVERED WITH BIOCOMPATIBLE POLYMERIC MATERIAL |
US5735892A (en) | 1993-08-18 | 1998-04-07 | W. L. Gore & Associates, Inc. | Intraluminal stent graft |
US6159565A (en) * | 1993-08-18 | 2000-12-12 | W. L. Gore & Associates, Inc. | Thin-wall intraluminal graft |
EP0714270B1 (en) * | 1993-08-18 | 2002-09-04 | W.L. Gore & Associates, Inc. | A tubular intraluminally insertable graft |
US6025044A (en) * | 1993-08-18 | 2000-02-15 | W. L. Gore & Associates, Inc. | Thin-wall polytetrafluoroethylene tube |
US6027779A (en) * | 1993-08-18 | 2000-02-22 | W. L. Gore & Associates, Inc. | Thin-wall polytetrafluoroethylene tube |
US5720300A (en) * | 1993-11-10 | 1998-02-24 | C. R. Bard, Inc. | High performance wires for use in medical devices and alloys therefor |
US6039749A (en) | 1994-02-10 | 2000-03-21 | Endovascular Systems, Inc. | Method and apparatus for deploying non-circular stents and graftstent complexes |
US5824041A (en) * | 1994-06-08 | 1998-10-20 | Medtronic, Inc. | Apparatus and methods for placement and repositioning of intraluminal prostheses |
US5683451A (en) | 1994-06-08 | 1997-11-04 | Cardiovascular Concepts, Inc. | Apparatus and methods for deployment release of intraluminal prostheses |
DE69518435T3 (en) | 1994-06-08 | 2004-07-22 | CardioVascular Concepts, Inc., Portola Valley | A branching graft manufacturing system |
US5636641A (en) | 1994-07-25 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | High strength member for intracorporeal use |
US6736843B1 (en) | 1994-07-25 | 2004-05-18 | Advanced Cardiovascular Systems, Inc. | Cylindrically-shaped balloon-expandable stent |
WO1996010366A1 (en) * | 1994-10-03 | 1996-04-11 | Heart Technology, Inc. | Transluminal thrombectomy apparatus |
US6558798B2 (en) | 1995-02-22 | 2003-05-06 | Scimed Life Systems, Inc. | Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US6638291B1 (en) | 1995-04-20 | 2003-10-28 | Micrus Corporation | Three dimensional, low friction vasoocclusive coil, and method of manufacture |
US8790363B2 (en) | 1995-04-20 | 2014-07-29 | DePuy Synthes Products, LLC | Three dimensional, low friction vasoocclusive coil, and method of manufacture |
US5674242A (en) * | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
FR2735967B1 (en) * | 1995-06-27 | 1998-03-06 | Perouse Implant Lab | VASCULAR SURGERY TOOL AND ITS USE |
US6991614B2 (en) | 1995-11-07 | 2006-01-31 | Boston Scientific Scimed, Inc. | Ureteral stent for improved patient comfort |
US5938682A (en) * | 1996-01-26 | 1999-08-17 | Cordis Corporation | Axially flexible stent |
US5895406A (en) * | 1996-01-26 | 1999-04-20 | Cordis Corporation | Axially flexible stent |
US5980553A (en) * | 1996-12-20 | 1999-11-09 | Cordis Corporation | Axially flexible stent |
US6258116B1 (en) | 1996-01-26 | 2001-07-10 | Cordis Corporation | Bifurcated axially flexible stent |
US5769870A (en) * | 1996-02-20 | 1998-06-23 | Cardiothoracic Systems, Inc. | Perfusion device for maintaining blood flow in a vessel while isolating an anastomosis |
US5925054A (en) | 1996-02-20 | 1999-07-20 | Cardiothoracic Systems, Inc. | Perfusion device for maintaining blood flow in a vessel while isolating an anastomosis |
EP0799607A3 (en) * | 1996-04-01 | 1998-10-21 | Medtronic, Inc. | Intravascular stent having flattened profile |
US5951586A (en) * | 1996-05-15 | 1999-09-14 | Medtronic, Inc. | Intraluminal stent |
US6190402B1 (en) | 1996-06-21 | 2001-02-20 | Musc Foundation For Research Development | Insitu formable and self-forming intravascular flow modifier (IFM) and IFM assembly for deployment of same |
US5972019A (en) * | 1996-07-25 | 1999-10-26 | Target Therapeutics, Inc. | Mechanical clot treatment device |
US6066158A (en) * | 1996-07-25 | 2000-05-23 | Target Therapeutics, Inc. | Mechanical clot encasing and removal wire |
US5718717A (en) | 1996-08-19 | 1998-02-17 | Bonutti; Peter M. | Suture anchor |
CA2213015A1 (en) * | 1996-08-23 | 1998-02-23 | Arterial Vascular Engineering, Inc. | A profiled stent and method of manufacture |
US7959664B2 (en) | 1996-12-26 | 2011-06-14 | Medinol, Ltd. | Flat process of drug coating for stents |
US5906759A (en) | 1996-12-26 | 1999-05-25 | Medinol Ltd. | Stent forming apparatus with stent deforming blades |
US6155264A (en) * | 1997-03-06 | 2000-12-05 | Scimed Life Systems, Inc. | Percutaneous bypass by tunneling through vessel wall |
US6974469B2 (en) * | 1997-03-06 | 2005-12-13 | Scimed Life Systems, Inc. | Distal protection device and method |
US5814064A (en) * | 1997-03-06 | 1998-09-29 | Scimed Life Systems, Inc. | Distal protection device |
US6026814A (en) * | 1997-03-06 | 2000-02-22 | Scimed Life Systems, Inc. | System and method for percutaneous coronary artery bypass |
US6035856A (en) * | 1997-03-06 | 2000-03-14 | Scimed Life Systems | Percutaneous bypass with branching vessel |
US5902475A (en) * | 1997-04-08 | 1999-05-11 | Interventional Technologies, Inc. | Method for manufacturing a stent |
US6726829B2 (en) | 1997-04-08 | 2004-04-27 | Scimed Life Systems, Inc. | Method of manufacturing a stent |
US5911734A (en) * | 1997-05-08 | 1999-06-15 | Embol-X, Inc. | Percutaneous catheter and guidewire having filter and medical device deployment capabilities |
US6676682B1 (en) | 1997-05-08 | 2004-01-13 | Scimed Life Systems, Inc. | Percutaneous catheter and guidewire having filter and medical device deployment capabilities |
US6213126B1 (en) | 1997-06-19 | 2001-04-10 | Scimed Life Systems, Inc. | Percutaneous artery to artery bypass using heart tissue as a portion of a bypass conduit |
US6092526A (en) * | 1997-06-19 | 2000-07-25 | Scimed Life Systems, Inc. | Percutaneous chamber-to-artery bypass |
US6443158B1 (en) | 1997-06-19 | 2002-09-03 | Scimed Life Systems, Inc. | Percutaneous coronary artery bypass through a venous vessel |
US6090118A (en) | 1998-07-23 | 2000-07-18 | Mcguckin, Jr.; James F. | Rotational thrombectomy apparatus and method with standing wave |
US20050216059A1 (en) | 2002-09-05 | 2005-09-29 | Bonutti Peter M | Method and apparatus for securing a suture |
US6070589A (en) | 1997-08-01 | 2000-06-06 | Teramed, Inc. | Methods for deploying bypass graft stents |
US6746476B1 (en) | 1997-09-22 | 2004-06-08 | Cordis Corporation | Bifurcated axially flexible stent |
US6066149A (en) * | 1997-09-30 | 2000-05-23 | Target Therapeutics, Inc. | Mechanical clot treatment device with distal filter |
US6461370B1 (en) * | 1998-11-03 | 2002-10-08 | C. R. Bard, Inc. | Temporary vascular filter guide wire |
US6159165A (en) | 1997-12-05 | 2000-12-12 | Micrus Corporation | Three dimensional spherical micro-coils manufactured from radiopaque nickel-titanium microstrand |
US6168570B1 (en) | 1997-12-05 | 2001-01-02 | Micrus Corporation | Micro-strand cable with enhanced radiopacity |
US6241691B1 (en) | 1997-12-05 | 2001-06-05 | Micrus Corporation | Coated superelastic stent |
US6045551A (en) | 1998-02-06 | 2000-04-04 | Bonutti; Peter M. | Bone suture |
US6290731B1 (en) | 1998-03-30 | 2001-09-18 | Cordis Corporation | Aortic graft having a precursor gasket for repairing an abdominal aortic aneurysm |
US6656215B1 (en) | 2000-11-16 | 2003-12-02 | Cordis Corporation | Stent graft having an improved means for attaching a stent to a graft |
US6013019A (en) * | 1998-04-06 | 2000-01-11 | Isostent, Inc. | Temporary radioisotope stent |
US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
US6494907B1 (en) | 1998-04-28 | 2002-12-17 | Intratherapeutics, Inc. | Braided stent |
US6511492B1 (en) * | 1998-05-01 | 2003-01-28 | Microvention, Inc. | Embolectomy catheters and methods for treating stroke and other small vessel thromboembolic disorders |
US6143021A (en) * | 1998-07-10 | 2000-11-07 | American Medical Systems, Inc. | Stent placement instrument and method of assembly |
US6165194A (en) | 1998-07-24 | 2000-12-26 | Micrus Corporation | Intravascular flow modifier and reinforcement device |
US6656218B1 (en) | 1998-07-24 | 2003-12-02 | Micrus Corporation | Intravascular flow modifier and reinforcement device |
US7736377B1 (en) * | 1998-08-03 | 2010-06-15 | Anson Medical Limited | Devices and methods for the repair of arteries |
US6325813B1 (en) | 1998-08-18 | 2001-12-04 | Scimed Life Systems, Inc. | Method and apparatus for stabilizing vascular wall |
US6500149B2 (en) | 1998-08-31 | 2002-12-31 | Deepak Gandhi | Apparatus for deployment of micro-coil using a catheter |
US6478773B1 (en) | 1998-12-21 | 2002-11-12 | Micrus Corporation | Apparatus for deployment of micro-coil using a catheter |
US6019779A (en) * | 1998-10-09 | 2000-02-01 | Intratherapeutics Inc. | Multi-filar coil medical stent |
US20020007145A1 (en) * | 1998-10-23 | 2002-01-17 | Timothy Stivland | Catheter having improved bonding region |
US6190403B1 (en) | 1998-11-13 | 2001-02-20 | Cordis Corporation | Low profile radiopaque stent with increased longitudinal flexibility and radial rigidity |
US6258118B1 (en) | 1998-11-25 | 2001-07-10 | Israel Aircraft Industries Ltd. | Removable support device |
US6413273B1 (en) | 1998-11-25 | 2002-07-02 | Israel Aircraft Industries Ltd. | Method and system for temporarily supporting a tubular organ |
US6835185B2 (en) | 1998-12-21 | 2004-12-28 | Micrus Corporation | Intravascular device deployment mechanism incorporating mechanical detachment |
US6120847A (en) * | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6171327B1 (en) | 1999-02-24 | 2001-01-09 | Scimed Life Systems, Inc. | Intravascular filter and method |
US6332892B1 (en) * | 1999-03-02 | 2001-12-25 | Scimed Life Systems, Inc. | Medical device with one or more helical coils |
US6162237A (en) * | 1999-04-19 | 2000-12-19 | Chan; Winston Kam Yew | Temporary intravascular stent for use in retrohepatic IVC or hepatic vein injury |
US6156373A (en) | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
US6458139B1 (en) | 1999-06-21 | 2002-10-01 | Endovascular Technologies, Inc. | Filter/emboli extractor for use in variable sized blood vessels |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US20030150821A1 (en) | 1999-07-16 | 2003-08-14 | Bates Mark C. | Emboli filtration system and methods of use |
US6530939B1 (en) | 1999-07-30 | 2003-03-11 | Incept, Llc | Vascular device having articulation region and methods of use |
US6544279B1 (en) | 2000-08-09 | 2003-04-08 | Incept, Llc | Vascular device for emboli, thrombus and foreign body removal and methods of use |
US6616679B1 (en) | 1999-07-30 | 2003-09-09 | Incept, Llc | Rapid exchange vascular device for emboli and thrombus removal and methods of use |
US6620182B1 (en) | 1999-07-30 | 2003-09-16 | Incept Llc | Vascular filter having articulation region and methods of use in the ascending aorta |
US6371970B1 (en) | 1999-07-30 | 2002-04-16 | Incept Llc | Vascular filter having articulation region and methods of use in the ascending aorta |
US6589263B1 (en) | 1999-07-30 | 2003-07-08 | Incept Llc | Vascular device having one or more articulation regions and methods of use |
US7306618B2 (en) * | 1999-07-30 | 2007-12-11 | Incept Llc | Vascular device for emboli and thrombi removal and methods of use |
US6142987A (en) | 1999-08-03 | 2000-11-07 | Scimed Life Systems, Inc. | Guided filter with support wire and methods of use |
US6235044B1 (en) | 1999-08-04 | 2001-05-22 | Scimed Life Systems, Inc. | Percutaneous catheter and guidewire for filtering during ablation of mycardial or vascular tissue |
US6168579B1 (en) | 1999-08-04 | 2001-01-02 | Scimed Life Systems, Inc. | Filter flush system and methods of use |
US6368343B1 (en) | 2000-03-13 | 2002-04-09 | Peter M. Bonutti | Method of using ultrasonic vibration to secure body tissue |
US6447516B1 (en) | 1999-08-09 | 2002-09-10 | Peter M. Bonutti | Method of securing tissue |
US8414543B2 (en) | 1999-10-22 | 2013-04-09 | Rex Medical, L.P. | Rotational thrombectomy wire with blocking device |
AU2614901A (en) | 1999-10-22 | 2001-04-30 | Boston Scientific Corporation | Double balloon thrombectomy catheter |
US6217589B1 (en) * | 1999-10-27 | 2001-04-17 | Scimed Life Systems, Inc. | Retrieval device made of precursor alloy cable and method of manufacturing |
US6371971B1 (en) | 1999-11-15 | 2002-04-16 | Scimed Life Systems, Inc. | Guidewire filter and methods of use |
US6673042B1 (en) * | 1999-11-22 | 2004-01-06 | Wilfred J. Samson | Expandable venous cannula and method of use |
US6635073B2 (en) | 2000-05-03 | 2003-10-21 | Peter M. Bonutti | Method of securing body tissue |
US7740637B2 (en) | 2000-02-09 | 2010-06-22 | Micrus Endovascular Corporation | Apparatus and method for deployment of a therapeutic device using a catheter |
US6540768B1 (en) | 2000-02-09 | 2003-04-01 | Cordis Corporation | Vascular filter system |
US9138222B2 (en) | 2000-03-13 | 2015-09-22 | P Tech, Llc | Method and device for securing body tissue |
US8932330B2 (en) * | 2000-03-13 | 2015-01-13 | P Tech, Llc | Method and device for securing body tissue |
US7094251B2 (en) | 2002-08-27 | 2006-08-22 | Marctec, Llc. | Apparatus and method for securing a suture |
US6514273B1 (en) | 2000-03-22 | 2003-02-04 | Endovascular Technologies, Inc. | Device for removal of thrombus through physiological adhesion |
US6817995B1 (en) * | 2000-04-20 | 2004-11-16 | Isotron ,Inc. | Reinforced catheter connector and system |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US6540775B1 (en) * | 2000-06-30 | 2003-04-01 | Cordis Corporation | Ultraflexible open cell stent |
US6746426B1 (en) * | 2000-07-11 | 2004-06-08 | Medtronic Vascular, Inc. | Transluminally deliverable vascular blockers and methods for facilitating retrograde flow of arterial blood through veins |
US6679902B1 (en) * | 2000-07-19 | 2004-01-20 | Advanced Cardiovascular Systems, Inc. | Reduced profile delivery sheath for use in interventional procedures |
US6485501B1 (en) | 2000-08-11 | 2002-11-26 | Cordis Corporation | Vascular filter system with guidewire and capture mechanism |
US20020072792A1 (en) * | 2000-09-22 | 2002-06-13 | Robert Burgermeister | Stent with optimal strength and radiopacity characteristics |
CA2424029C (en) | 2000-09-29 | 2008-01-29 | Cordis Corporation | Coated medical devices |
US6616681B2 (en) | 2000-10-05 | 2003-09-09 | Scimed Life Systems, Inc. | Filter delivery and retrieval device |
EP1347794A2 (en) * | 2000-11-27 | 2003-10-01 | Medtronic, Inc. | Stents and methods for preparing stents from wires having hydrogel coating layers thereon |
US6663651B2 (en) | 2001-01-16 | 2003-12-16 | Incept Llc | Systems and methods for vascular filter retrieval |
US7169165B2 (en) * | 2001-01-16 | 2007-01-30 | Boston Scientific Scimed, Inc. | Rapid exchange sheath for deployment of medical devices and methods of use |
US6936059B2 (en) * | 2001-01-16 | 2005-08-30 | Scimed Life Systems, Inc. | Endovascular guidewire filter and methods of use |
US6610077B1 (en) * | 2001-01-23 | 2003-08-26 | Endovascular Technologies, Inc. | Expandable emboli filter and thrombectomy device |
US6689151B2 (en) | 2001-01-25 | 2004-02-10 | Scimed Life Systems, Inc. | Variable wall thickness for delivery sheath housing |
US6840950B2 (en) | 2001-02-20 | 2005-01-11 | Scimed Life Systems, Inc. | Low profile emboli capture device |
US20020123755A1 (en) * | 2001-03-01 | 2002-09-05 | Scimed Life Systems, Inc. | Embolic protection filter delivery sheath |
US7226464B2 (en) * | 2001-03-01 | 2007-06-05 | Scimed Life Systems, Inc. | Intravascular filter retrieval device having an actuatable dilator tip |
US6679911B2 (en) | 2001-03-01 | 2004-01-20 | Cordis Corporation | Flexible stent |
US6740114B2 (en) | 2001-03-01 | 2004-05-25 | Cordis Corporation | Flexible stent |
US6790227B2 (en) | 2001-03-01 | 2004-09-14 | Cordis Corporation | Flexible stent |
AU784552B2 (en) | 2001-03-02 | 2006-05-04 | Cardinal Health 529, Llc | Flexible stent |
US6537295B2 (en) | 2001-03-06 | 2003-03-25 | Scimed Life Systems, Inc. | Wire and lock mechanism |
US6719804B2 (en) | 2001-04-02 | 2004-04-13 | Scimed Life Systems, Inc. | Medical stent and related methods |
US8182527B2 (en) | 2001-05-07 | 2012-05-22 | Cordis Corporation | Heparin barrier coating for controlled drug release |
US6814739B2 (en) | 2001-05-18 | 2004-11-09 | U.S. Endoscopy Group, Inc. | Retrieval device |
US8252040B2 (en) | 2001-07-20 | 2012-08-28 | Microvention, Inc. | Aneurysm treatment device and method of use |
US20030023263A1 (en) | 2001-07-24 | 2003-01-30 | Incept Llc | Apparatus and methods for aspirating emboli |
US20030023261A1 (en) | 2001-07-30 | 2003-01-30 | Scimed Life Systems Inc. | Chronic total occlusion device with variable stiffness shaft |
JP4351405B2 (en) * | 2001-08-29 | 2009-10-28 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Transcoding system and annotation management device |
US7252679B2 (en) * | 2001-09-13 | 2007-08-07 | Cordis Corporation | Stent with angulated struts |
US6755847B2 (en) | 2001-10-05 | 2004-06-29 | Scimed Life Systems, Inc. | Emboli capturing device and method of manufacture therefor |
US6620202B2 (en) | 2001-10-16 | 2003-09-16 | Scimed Life Systems, Inc. | Medical stent with variable coil and related methods |
US6887257B2 (en) * | 2001-10-19 | 2005-05-03 | Incept Llc | Vascular embolic filter exchange devices and methods of use thereof |
US20040111108A1 (en) * | 2001-11-09 | 2004-06-10 | Farnan Robert C. | Balloon catheter with non-deployable stent |
ATE384488T1 (en) | 2001-11-09 | 2008-02-15 | Rubicon Medical Inc | STENT DEPLOYMENT DEVICE WITH EMBOLIC PROTECTION |
ES2320742T3 (en) * | 2001-11-09 | 2009-05-28 | Angioscore, Inc. | BALL CATHETER WITH NON-DISPLAYABLE ENDOPROTESIS. |
US6719765B2 (en) | 2001-12-03 | 2004-04-13 | Bonutti 2003 Trust-A | Magnetic suturing system and method |
US7153320B2 (en) | 2001-12-13 | 2006-12-26 | Scimed Life Systems, Inc. | Hydraulic controlled retractable tip filter retrieval catheter |
US6793666B2 (en) * | 2001-12-18 | 2004-09-21 | Scimed Life Systems, Inc. | Distal protection mechanically attached filter cartridge |
US6932830B2 (en) | 2002-01-10 | 2005-08-23 | Scimed Life Systems, Inc. | Disc shaped filter |
US8647359B2 (en) | 2002-01-10 | 2014-02-11 | Boston Scientific Scimed, Inc. | Distal protection filter |
US20030135162A1 (en) * | 2002-01-17 | 2003-07-17 | Scimed Life Systems, Inc. | Delivery and retrieval manifold for a distal protection filter |
US7029493B2 (en) * | 2002-01-25 | 2006-04-18 | Cordis Corporation | Stent with enhanced crossability |
US6997938B2 (en) * | 2002-02-12 | 2006-02-14 | Scimed Life Systems, Inc. | Embolic protection device |
US7118539B2 (en) * | 2002-02-26 | 2006-10-10 | Scimed Life Systems, Inc. | Articulating guide wire for embolic protection and methods of use |
US7029440B2 (en) * | 2002-03-13 | 2006-04-18 | Scimed Life Systems, Inc. | Distal protection filter and method of manufacture |
US9155544B2 (en) | 2002-03-20 | 2015-10-13 | P Tech, Llc | Robotic systems and methods |
US8721713B2 (en) * | 2002-04-23 | 2014-05-13 | Medtronic, Inc. | System for implanting a replacement valve |
US7519418B2 (en) * | 2002-04-30 | 2009-04-14 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
US7060082B2 (en) | 2002-05-06 | 2006-06-13 | Scimed Life Systems, Inc. | Perfusion guidewire in combination with a distal filter |
US8070769B2 (en) | 2002-05-06 | 2011-12-06 | Boston Scientific Scimed, Inc. | Inverted embolic protection filter |
US7585309B2 (en) * | 2002-05-16 | 2009-09-08 | Boston Scientific Scimed, Inc. | Aortic filter |
US7001406B2 (en) * | 2002-05-23 | 2006-02-21 | Scimed Life Systems Inc. | Cartridge embolic protection filter and methods of use |
US7959584B2 (en) * | 2002-05-29 | 2011-06-14 | Boston Scientific Scimed, Inc. | Dedicated distal protection guidewires |
US7326224B2 (en) * | 2002-06-11 | 2008-02-05 | Boston Scientific Scimed, Inc. | Shaft and wire lock |
US8425549B2 (en) | 2002-07-23 | 2013-04-23 | Reverse Medical Corporation | Systems and methods for removing obstructive matter from body lumens and treating vascular defects |
US7357854B1 (en) | 2002-08-19 | 2008-04-15 | Advanced Cardiovascular Systems, Inc. | Process for electropolishing a device made from cobalt-chromium |
US7115138B2 (en) * | 2002-09-04 | 2006-10-03 | Boston Scientific Scimed, Inc. | Sheath tip |
US7174636B2 (en) * | 2002-09-04 | 2007-02-13 | Scimed Life Systems, Inc. | Method of making an embolic filter |
US8920432B2 (en) * | 2002-09-24 | 2014-12-30 | Medtronic, Inc. | Lead delivery device and method |
US9636499B2 (en) * | 2002-09-24 | 2017-05-02 | Medtronic, Inc. | Lead delivery device and method |
US9480839B2 (en) * | 2002-09-24 | 2016-11-01 | Medtronic, Inc. | Lead delivery device and method |
US8229572B2 (en) * | 2008-06-27 | 2012-07-24 | Medtronic, Inc. | Lead delivery device and method |
US9849279B2 (en) * | 2008-06-27 | 2017-12-26 | Medtronic, Inc. | Lead delivery device and method |
US7107105B2 (en) * | 2002-09-24 | 2006-09-12 | Medtronic, Inc. | Deployable medical lead fixation system and method |
US8468678B2 (en) | 2002-10-02 | 2013-06-25 | Boston Scientific Scimed, Inc. | Expandable retrieval device |
US7998163B2 (en) | 2002-10-03 | 2011-08-16 | Boston Scientific Scimed, Inc. | Expandable retrieval device |
US7481823B2 (en) * | 2002-10-25 | 2009-01-27 | Boston Scientific Scimed, Inc. | Multiple membrane embolic protection filter |
WO2004043507A1 (en) * | 2002-11-07 | 2004-05-27 | Carbon Medical Technologies, Inc. | Biocompatible medical device coatings |
US20040102789A1 (en) * | 2002-11-22 | 2004-05-27 | Scimed Life Systems, Inc. | Selectively locking device |
US7128752B2 (en) * | 2002-12-23 | 2006-10-31 | Syntheon, Llc | Emboli and thrombi filter device and method of using the same |
US7625389B2 (en) | 2002-12-30 | 2009-12-01 | Boston Scientific Scimed, Inc. | Embolic protection device |
US8080026B2 (en) | 2003-01-21 | 2011-12-20 | Angioscore, Inc. | Apparatus and methods for treating hardened vascular lesions |
US20040147955A1 (en) * | 2003-01-28 | 2004-07-29 | Scimed Life Systems, Inc. | Embolic protection filter having an improved filter frame |
US7163549B2 (en) * | 2003-02-11 | 2007-01-16 | Boston Scientific Scimed Inc. | Filter membrane manufacturing method |
US7740644B2 (en) * | 2003-02-24 | 2010-06-22 | Boston Scientific Scimed, Inc. | Embolic protection filtering device that can be adapted to be advanced over a guidewire |
US7137991B2 (en) | 2003-02-24 | 2006-11-21 | Scimed Life Systems, Inc. | Multi-wire embolic protection filtering device |
US6878291B2 (en) * | 2003-02-24 | 2005-04-12 | Scimed Life Systems, Inc. | Flexible tube for cartridge filter |
US7163550B2 (en) | 2003-03-26 | 2007-01-16 | Scimed Life Systems, Inc. | Method for manufacturing medical devices from linear elastic materials while maintaining linear elastic properties |
US6960370B2 (en) * | 2003-03-27 | 2005-11-01 | Scimed Life Systems, Inc. | Methods of forming medical devices |
US6902572B2 (en) | 2003-04-02 | 2005-06-07 | Scimed Life Systems, Inc. | Anchoring mechanisms for intravascular devices |
US7857916B2 (en) | 2003-04-11 | 2010-12-28 | Nhk Spring Co., Ltd | Co-Cr-Mo alloy fine wire, manufacturing method therefor, and planar body, tubular body, stranded wire and cable formed of wire |
US7497864B2 (en) | 2003-04-30 | 2009-03-03 | Marctec, Llc. | Tissue fastener and methods for using same |
US7780611B2 (en) | 2003-05-01 | 2010-08-24 | Boston Scientific Scimed, Inc. | Medical instrument with controlled torque transmission |
US6969396B2 (en) | 2003-05-07 | 2005-11-29 | Scimed Life Systems, Inc. | Filter membrane with increased surface area |
US7537600B2 (en) | 2003-06-12 | 2009-05-26 | Boston Scientific Scimed, Inc. | Valved embolic protection filter |
US8337519B2 (en) | 2003-07-10 | 2012-12-25 | Boston Scientific Scimed, Inc. | Embolic protection filtering device |
US9301829B2 (en) * | 2003-07-30 | 2016-04-05 | Boston Scientific Scimed, Inc. | Embolic protection aspirator |
US7731722B2 (en) * | 2003-07-31 | 2010-06-08 | Vance Products Incorporated | Ureteral backstop filter and retrieval device |
US8535344B2 (en) | 2003-09-12 | 2013-09-17 | Rubicon Medical, Inc. | Methods, systems, and devices for providing embolic protection and removing embolic material |
US7651514B2 (en) | 2003-12-11 | 2010-01-26 | Boston Scientific Scimed, Inc. | Nose rider improvement for filter exchange and methods of use |
US7955313B2 (en) * | 2003-12-17 | 2011-06-07 | Boston Scientific Scimed, Inc. | Composite catheter braid |
US7763011B2 (en) * | 2003-12-22 | 2010-07-27 | Boston Scientific Scimed, Inc. | Variable density braid stent |
US20080039873A1 (en) | 2004-03-09 | 2008-02-14 | Marctec, Llc. | Method and device for securing body tissue |
US20060206200A1 (en) | 2004-05-25 | 2006-09-14 | Chestnut Medical Technologies, Inc. | Flexible vascular occluding device |
US8617234B2 (en) | 2004-05-25 | 2013-12-31 | Covidien Lp | Flexible vascular occluding device |
US8267985B2 (en) | 2005-05-25 | 2012-09-18 | Tyco Healthcare Group Lp | System and method for delivering and deploying an occluding device within a vessel |
SG175723A1 (en) | 2004-05-25 | 2011-12-29 | Tyco Healthcare | Vascular stenting for aneurysms |
WO2005115120A2 (en) * | 2004-05-25 | 2005-12-08 | U.S. Endoscopy Group, Inc. | Retrieval device |
US8623067B2 (en) | 2004-05-25 | 2014-01-07 | Covidien Lp | Methods and apparatus for luminal stenting |
EP1750619B1 (en) | 2004-05-25 | 2013-07-24 | Covidien LP | Flexible vascular occluding device |
US8241315B2 (en) | 2004-06-24 | 2012-08-14 | Boston Scientific Scimed, Inc. | Apparatus and method for treating occluded vasculature |
US7794472B2 (en) | 2004-08-11 | 2010-09-14 | Boston Scientific Scimed, Inc. | Single wire intravascular filter |
US7621904B2 (en) | 2004-10-21 | 2009-11-24 | Boston Scientific Scimed, Inc. | Catheter with a pre-shaped distal tip |
US9271766B2 (en) | 2004-10-26 | 2016-03-01 | P Tech, Llc | Devices and methods for stabilizing tissue and implants |
US9463012B2 (en) | 2004-10-26 | 2016-10-11 | P Tech, Llc | Apparatus for guiding and positioning an implant |
US20060089646A1 (en) | 2004-10-26 | 2006-04-27 | Bonutti Peter M | Devices and methods for stabilizing tissue and implants |
US9173647B2 (en) | 2004-10-26 | 2015-11-03 | P Tech, Llc | Tissue fixation system |
US20060106451A1 (en) * | 2004-11-18 | 2006-05-18 | Yuri Busiashvili | Electronic anti-coagulation stent for intra-arterial deployment |
US8038696B2 (en) | 2004-12-06 | 2011-10-18 | Boston Scientific Scimed, Inc. | Sheath for use with an embolic protection filter |
US20060129226A1 (en) * | 2004-12-10 | 2006-06-15 | Robert Burgermeister | Material for flexible connectors in high strength, high flexibility, controlled recoil stent |
US20060136040A1 (en) * | 2004-12-17 | 2006-06-22 | Robert Burgermeister | Longitudinal design and improved material for flexible connectors in high strength, high flexibility, controlled recoil stent |
US8480629B2 (en) | 2005-01-28 | 2013-07-09 | Boston Scientific Scimed, Inc. | Universal utility board for use with medical devices and methods of use |
US9089323B2 (en) | 2005-02-22 | 2015-07-28 | P Tech, Llc | Device and method for securing body tissue |
US20060229638A1 (en) * | 2005-03-29 | 2006-10-12 | Abrams Robert M | Articulating retrieval device |
US7330765B2 (en) * | 2005-04-25 | 2008-02-12 | Cardiac Pacemakers, Inc. | Cardiac lead having self-expanding fixation features |
US7477946B2 (en) * | 2005-04-26 | 2009-01-13 | Cardiac Pacemakers, Inc. | Fixation device for coronary venous lead |
US8175724B2 (en) * | 2005-04-26 | 2012-05-08 | Cardiac Pacemakers, Inc. | Vascular fixation device |
US20060253184A1 (en) * | 2005-05-04 | 2006-11-09 | Kurt Amplatz | System for the controlled delivery of stents and grafts |
US20070118207A1 (en) * | 2005-05-04 | 2007-05-24 | Aga Medical Corporation | System for controlled delivery of stents and grafts |
US10076641B2 (en) | 2005-05-11 | 2018-09-18 | The Spectranetics Corporation | Methods and systems for delivering substances into luminal walls |
US8273101B2 (en) | 2005-05-25 | 2012-09-25 | Tyco Healthcare Group Lp | System and method for delivering and deploying an occluding device within a vessel |
JP4945714B2 (en) | 2005-05-25 | 2012-06-06 | タイコ ヘルスケア グループ リミテッド パートナーシップ | System and method for supplying and deploying an occlusion device in a conduit |
US8019438B2 (en) * | 2005-06-28 | 2011-09-13 | Cardiac Pacemakers, Inc. | Anchor for electrode delivery system |
US9101949B2 (en) | 2005-08-04 | 2015-08-11 | Eilaz Babaev | Ultrasonic atomization and/or seperation system |
US7896539B2 (en) | 2005-08-16 | 2011-03-01 | Bacoustics, Llc | Ultrasound apparatus and methods for mixing liquids and coating stents |
WO2007022592A1 (en) | 2005-08-25 | 2007-03-01 | Baker Medical Research Institute | Devices and methods for perfusing an organ |
WO2007092820A2 (en) | 2006-02-03 | 2007-08-16 | Lazarus Effect, Inc. | Methods and devices for restoring blood flow within blocked vasculature |
US11278331B2 (en) | 2006-02-07 | 2022-03-22 | P Tech Llc | Method and devices for intracorporeal bonding of implants with thermal energy |
US7967820B2 (en) | 2006-02-07 | 2011-06-28 | P Tech, Llc. | Methods and devices for trauma welding |
US8496657B2 (en) | 2006-02-07 | 2013-07-30 | P Tech, Llc. | Methods for utilizing vibratory energy to weld, stake and/or remove implants |
US11253296B2 (en) | 2006-02-07 | 2022-02-22 | P Tech, Llc | Methods and devices for intracorporeal bonding of implants with thermal energy |
US8152833B2 (en) | 2006-02-22 | 2012-04-10 | Tyco Healthcare Group Lp | Embolic protection systems having radiopaque filter mesh |
US8828077B2 (en) | 2006-03-15 | 2014-09-09 | Medinol Ltd. | Flat process of preparing drug eluting stents |
US11246638B2 (en) | 2006-05-03 | 2022-02-15 | P Tech, Llc | Methods and devices for utilizing bondable materials |
US9585743B2 (en) | 2006-07-31 | 2017-03-07 | Edwards Lifesciences Cardiaq Llc | Surgical implant devices and methods for their manufacture and use |
WO2008016578A2 (en) | 2006-07-31 | 2008-02-07 | Cartledge Richard G | Sealable endovascular implants and methods for their use |
US9408607B2 (en) | 2009-07-02 | 2016-08-09 | Edwards Lifesciences Cardiaq Llc | Surgical implant devices and methods for their manufacture and use |
US7865249B2 (en) * | 2006-09-22 | 2011-01-04 | Cardiac Pacemakers, Inc. | Means to securely fixate pacing leads and/or sensors in vessels |
WO2008091991A2 (en) * | 2007-01-25 | 2008-07-31 | Trinity Health-Michigan | Blood vessel occluder and method of use |
US8617185B2 (en) | 2007-02-13 | 2013-12-31 | P Tech, Llc. | Fixation device |
US20080200974A1 (en) * | 2007-02-15 | 2008-08-21 | Cardiac Innovations, Llc | Drug Eluting Stent System with Controlled Self Expansion |
US8000810B2 (en) * | 2007-03-20 | 2011-08-16 | Cardiac Pacemakers, Inc. | Systems and methods for transvenous lead implantation |
US8591521B2 (en) | 2007-06-08 | 2013-11-26 | United States Endoscopy Group, Inc. | Retrieval device |
EP2162101B1 (en) | 2007-06-25 | 2019-02-20 | MicroVention, Inc. | Self-expanding prosthesis |
US7753285B2 (en) | 2007-07-13 | 2010-07-13 | Bacoustics, Llc | Echoing ultrasound atomization and/or mixing system |
US7780095B2 (en) | 2007-07-13 | 2010-08-24 | Bacoustics, Llc | Ultrasound pumping apparatus |
US9814611B2 (en) | 2007-07-31 | 2017-11-14 | Edwards Lifesciences Cardiaq Llc | Actively controllable stent, stent graft, heart valve and method of controlling same |
US9566178B2 (en) | 2010-06-24 | 2017-02-14 | Edwards Lifesciences Cardiaq Llc | Actively controllable stent, stent graft, heart valve and method of controlling same |
US9034007B2 (en) | 2007-09-21 | 2015-05-19 | Insera Therapeutics, Inc. | Distal embolic protection devices with a variable thickness microguidewire and methods for their use |
US20090082838A1 (en) * | 2007-09-26 | 2009-03-26 | Cardiac Pacemakers, Inc. | Left-ventricular lead fixation device in coronary veins |
US8066757B2 (en) | 2007-10-17 | 2011-11-29 | Mindframe, Inc. | Blood flow restoration and thrombus management methods |
US9198687B2 (en) | 2007-10-17 | 2015-12-01 | Covidien Lp | Acute stroke revascularization/recanalization systems processes and products thereby |
US11337714B2 (en) | 2007-10-17 | 2022-05-24 | Covidien Lp | Restoring blood flow and clot removal during acute ischemic stroke |
US20100022951A1 (en) * | 2008-05-19 | 2010-01-28 | Luce, Forward, Hamilton 7 Scripps, Llp | Detachable hub/luer device and processes |
US10123803B2 (en) | 2007-10-17 | 2018-11-13 | Covidien Lp | Methods of managing neurovascular obstructions |
US8585713B2 (en) | 2007-10-17 | 2013-11-19 | Covidien Lp | Expandable tip assembly for thrombus management |
US9220522B2 (en) | 2007-10-17 | 2015-12-29 | Covidien Lp | Embolus removal systems with baskets |
US8088140B2 (en) | 2008-05-19 | 2012-01-03 | Mindframe, Inc. | Blood flow restorative and embolus removal methods |
US8926680B2 (en) | 2007-11-12 | 2015-01-06 | Covidien Lp | Aneurysm neck bridging processes with revascularization systems methods and products thereby |
JP5457373B2 (en) | 2008-02-22 | 2014-04-02 | コヴィディエン リミテッド パートナーシップ | Device for blood flow recovery |
WO2009126935A2 (en) | 2008-04-11 | 2009-10-15 | Mindframe, Inc. | Monorail neuro-microcatheter for delivery of medical devices to treat stroke, processes and products thereby |
WO2009140437A1 (en) | 2008-05-13 | 2009-11-19 | Nfocus Neuromedical, Inc. | Braid implant delivery systems |
US9775989B2 (en) * | 2008-06-27 | 2017-10-03 | Medtronic, Inc. | Lead delivery device and method |
US11931523B2 (en) | 2008-06-27 | 2024-03-19 | Medtronic, Inc. | Lead delivery device and method |
US9775990B2 (en) * | 2008-06-27 | 2017-10-03 | Medtronic, Inc. | Lead delivery device and method |
US9402707B2 (en) | 2008-07-22 | 2016-08-02 | Neuravi Limited | Clot capture systems and associated methods |
US8777976B2 (en) | 2008-07-22 | 2014-07-15 | Neuravi Limited | Clot capture systems and associated methods |
US8444669B2 (en) | 2008-12-15 | 2013-05-21 | Boston Scientific Scimed, Inc. | Embolic filter delivery system and method |
US20100160951A1 (en) * | 2008-12-19 | 2010-06-24 | Madison Michael T | Intracranial blood vessel dilation device |
CA2753592A1 (en) | 2009-02-24 | 2010-09-02 | P Tech, Llc | Methods and devices for utilizing bondable materials |
WO2010102307A1 (en) | 2009-03-06 | 2010-09-10 | Lazarus Effect, Inc. | Retrieval systems and methods for use thereof |
US10772717B2 (en) | 2009-05-01 | 2020-09-15 | Endologix, Inc. | Percutaneous method and device to treat dissections |
JP2012525239A (en) | 2009-05-01 | 2012-10-22 | エンドロジックス、インク | Transcutaneous methods and devices for treating dissociation (priority information and incorporation by reference) |
US9309347B2 (en) | 2009-05-20 | 2016-04-12 | Biomedical, Inc. | Bioresorbable thermoset polyester/urethane elastomers |
US20110319987A1 (en) | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
US8888840B2 (en) * | 2009-05-20 | 2014-11-18 | Boston Scientific Scimed, Inc. | Drug eluting medical implant |
US8992601B2 (en) | 2009-05-20 | 2015-03-31 | 480 Biomedical, Inc. | Medical implants |
US9265633B2 (en) | 2009-05-20 | 2016-02-23 | 480 Biomedical, Inc. | Drug-eluting medical implants |
US8137396B2 (en) * | 2009-05-20 | 2012-03-20 | 480 Biomedical, Inc | Medical implant |
CA2763324C (en) | 2009-05-28 | 2018-10-23 | Avinger, Inc. | Optical coherence tomography for biological imaging |
WO2011017123A2 (en) | 2009-07-27 | 2011-02-10 | Endologix, Inc. | Stent graft |
US8740961B2 (en) | 2009-08-13 | 2014-06-03 | Richard Eustis Fulton, III | Method for treating a target site in a vascular body channel |
US9999531B2 (en) * | 2009-08-24 | 2018-06-19 | Qualimed Innovative Medizinprodukte Gmbh | Variable scale stent deployment device |
US9199066B2 (en) | 2010-03-12 | 2015-12-01 | Quattro Vascular Pte Ltd. | Device and method for compartmental vessel treatment |
US8658006B2 (en) | 2010-04-12 | 2014-02-25 | Abbott Cardiovascular Systems Inc. | System and method for electropolising devices |
EP2380604A1 (en) | 2010-04-19 | 2011-10-26 | InnoRa Gmbh | Improved coating formulations for scoring or cutting balloon catheters |
US9144455B2 (en) | 2010-06-07 | 2015-09-29 | Just Right Surgical, Llc | Low power tissue sealing device and method |
BR122020016721B8 (en) | 2010-06-14 | 2022-04-12 | Maquet Cardiovascular Llc | Cirurgical instruments |
WO2012009675A2 (en) | 2010-07-15 | 2012-01-19 | Lazarus Effect, Inc. | Retrieval systems and methods for use thereof |
US8632559B2 (en) | 2010-09-21 | 2014-01-21 | Angioscore, Inc. | Method and system for treating valve stenosis |
US9463036B2 (en) | 2010-10-22 | 2016-10-11 | Neuravi Limited | Clot engagement and removal system |
WO2012068298A1 (en) | 2010-11-17 | 2012-05-24 | Endologix, Inc. | Devices and methods to treat vascular dissections |
US8821478B2 (en) | 2011-03-04 | 2014-09-02 | Boston Scientific Scimed, Inc. | Catheter with variable stiffness |
US11259824B2 (en) | 2011-03-09 | 2022-03-01 | Neuravi Limited | Clot retrieval device for removing occlusive clot from a blood vessel |
ES2871050T3 (en) | 2011-03-09 | 2021-10-28 | Neuravi Ltd | A clot retrieval device to remove the occlusive clot from a blood vessel |
EP3135232B1 (en) | 2011-03-28 | 2018-05-02 | Avinger, Inc. | Occlusion-crossing devices, imaging, and atherectomy devices |
WO2012155093A1 (en) | 2011-05-11 | 2012-11-15 | Microvention, Inc. | Device for occluding a lumen |
US8814932B2 (en) | 2011-05-17 | 2014-08-26 | Boston Scientific Scimed, Inc. | Annuloplasty ring with piercing wire and segmented wire lumen |
EP2709559B1 (en) | 2011-05-17 | 2015-01-21 | Boston Scientific Scimed, Inc. | Annuloplasty ring with anchors fixed by curing polymer |
US8747462B2 (en) | 2011-05-17 | 2014-06-10 | Boston Scientific Scimed, Inc. | Corkscrew annuloplasty device |
BR112013030183A2 (en) | 2011-05-23 | 2017-12-05 | Lazarus Effect Inc | interventional medical device for recovering and securing an obstruction within a vessel lumen, method of securing an obstruction within a vessel, method of preparing a retrieval device, medical device retrieval system, for securing an obstruction within a lumen and for use with a catheter configured to be navigated through the vasculature, interventional medical device to secure a retrieval device having one or more obstructions located therein for removal of a body and stent retrieval device to expand against one or more occlusive bodies in a vasculature |
US9827093B2 (en) | 2011-10-21 | 2017-11-28 | Edwards Lifesciences Cardiaq Llc | Actively controllable stent, stent graft, heart valve and method of controlling same |
CH705978A1 (en) * | 2012-01-11 | 2013-07-15 | Qvanteq Ag | Method and device for determining a surface characteristic of stents and stent with defined surface characteristics. |
WO2013114201A1 (en) | 2012-02-01 | 2013-08-08 | Tanhum Feld | Device for compartmental dilatation of blood vessels |
US9216033B2 (en) | 2012-02-08 | 2015-12-22 | Quattro Vascular Pte Ltd. | System and method for treating biological vessels |
EP2811947B1 (en) | 2012-02-08 | 2019-03-27 | TriReme Medical, LLC | Constraining structure with non-linear axial struts |
WO2013172972A1 (en) | 2012-05-14 | 2013-11-21 | Avinger, Inc. | Optical coherence tomography with graded index fiber for biological imaging |
JP5897406B2 (en) * | 2012-05-28 | 2016-03-30 | 株式会社石飛製作所 | Electrolytic solution for electropolishing |
US9155647B2 (en) | 2012-07-18 | 2015-10-13 | Covidien Lp | Methods and apparatus for luminal stenting |
US9114001B2 (en) | 2012-10-30 | 2015-08-25 | Covidien Lp | Systems for attaining a predetermined porosity of a vascular device |
US9452070B2 (en) | 2012-10-31 | 2016-09-27 | Covidien Lp | Methods and systems for increasing a density of a region of a vascular device |
US9943427B2 (en) | 2012-11-06 | 2018-04-17 | Covidien Lp | Shaped occluding devices and methods of using the same |
EP3967266B1 (en) | 2012-11-15 | 2023-07-12 | Nfinium Vascular Technologies, LLC | Temporary vascular scaffold and scoring device |
WO2014105713A1 (en) * | 2012-12-28 | 2014-07-03 | Volcano Corporation | Intravascular ultrasound catheter for minimizing image distortion |
US10076377B2 (en) | 2013-01-05 | 2018-09-18 | P Tech, Llc | Fixation systems and methods |
US9157174B2 (en) | 2013-02-05 | 2015-10-13 | Covidien Lp | Vascular device for aneurysm treatment and providing blood flow into a perforator vessel |
US9642635B2 (en) | 2013-03-13 | 2017-05-09 | Neuravi Limited | Clot removal device |
CN109157304B (en) | 2013-03-14 | 2021-12-31 | 尼尔拉维有限公司 | A clot retrieval device for removing a clogged clot from a blood vessel |
SI2967611T1 (en) | 2013-03-14 | 2019-04-30 | Neuravi Limited | Devices for removal of acute blockages from blood vessels |
US9433429B2 (en) | 2013-03-14 | 2016-09-06 | Neuravi Limited | Clot retrieval devices |
US8690907B1 (en) | 2013-03-15 | 2014-04-08 | Insera Therapeutics, Inc. | Vascular treatment methods |
US8679150B1 (en) | 2013-03-15 | 2014-03-25 | Insera Therapeutics, Inc. | Shape-set textile structure based mechanical thrombectomy methods |
EP2967507B1 (en) * | 2013-03-15 | 2018-09-05 | Avinger, Inc. | Tissue collection device for catheter |
EP2967371A4 (en) | 2013-03-15 | 2016-12-07 | Avinger Inc | Chronic total occlusion crossing devices with imaging |
WO2014142958A1 (en) | 2013-03-15 | 2014-09-18 | Avinger, Inc. | Optical pressure sensor assembly |
US8715314B1 (en) | 2013-03-15 | 2014-05-06 | Insera Therapeutics, Inc. | Vascular treatment measurement methods |
EP2968872B1 (en) | 2013-03-15 | 2019-09-25 | Insera Therapeutics, Inc. | Vascular treatment devices |
EP3019096B1 (en) | 2013-07-08 | 2023-07-05 | Avinger, Inc. | System for identification of elastic lamina to guide interventional therapy |
US9545325B2 (en) | 2013-08-08 | 2017-01-17 | Covidien Lp | Medical device delivery control mechanism |
US9572591B2 (en) | 2013-09-03 | 2017-02-21 | United States Endoscopy Group, Inc. | Endoscopic snare device |
US10117668B2 (en) | 2013-10-08 | 2018-11-06 | The Spectranetics Corporation | Balloon catheter with non-deployable stent having improved stability |
US10285720B2 (en) | 2014-03-11 | 2019-05-14 | Neuravi Limited | Clot retrieval system for removing occlusive clot from a blood vessel |
US10792056B2 (en) | 2014-06-13 | 2020-10-06 | Neuravi Limited | Devices and methods for removal of acute blockages from blood vessels |
US10441301B2 (en) | 2014-06-13 | 2019-10-15 | Neuravi Limited | Devices and methods for removal of acute blockages from blood vessels |
US10265086B2 (en) | 2014-06-30 | 2019-04-23 | Neuravi Limited | System for removing a clot from a blood vessel |
MX2017000303A (en) | 2014-07-08 | 2017-07-10 | Avinger Inc | High speed chronic total occlusion crossing devices. |
GB2529249B (en) | 2014-08-15 | 2017-09-27 | Cook Medical Technologies Llc | Endoluminal drug delivery device |
JP6803838B2 (en) | 2014-11-17 | 2020-12-23 | トライレム・メディカル・エルエルシー | Balloon catheter system and how to use this system |
US10617435B2 (en) | 2014-11-26 | 2020-04-14 | Neuravi Limited | Clot retrieval device for removing clot from a blood vessel |
US11253278B2 (en) | 2014-11-26 | 2022-02-22 | Neuravi Limited | Clot retrieval system for removing occlusive clot from a blood vessel |
JP2017535352A (en) | 2014-11-26 | 2017-11-30 | ニューラヴィ・リミテッド | Clot collection device for removing obstructive clots from blood vessels |
CN107405470A (en) | 2015-02-11 | 2017-11-28 | 柯惠有限合伙公司 | With expansible sophisticated medical treatment device and method |
US10058393B2 (en) | 2015-10-21 | 2018-08-28 | P Tech, Llc | Systems and methods for navigation and visualization |
JP2019508201A (en) | 2016-02-16 | 2019-03-28 | インセラ セラピューティクス,インク. | Suction device and fixed blood flow bypass device |
US10065018B2 (en) | 2016-03-16 | 2018-09-04 | Krishna Rocha-Singh | Apparatus and method for promoting angiogenesis in ischemic tissue |
US10610669B2 (en) | 2016-03-16 | 2020-04-07 | Krishna Rocha-Singh, M.D. | Apparatus and method for promoting angiogenesis in ischemic tissue |
WO2017173370A1 (en) | 2016-04-01 | 2017-10-05 | Avinger, Inc. | Atherectomy catheter with serrated cutter |
WO2017201263A1 (en) * | 2016-05-19 | 2017-11-23 | University Of Iowa Research Foundation | Microcatheter stent |
DE102016110199A1 (en) * | 2016-06-02 | 2017-12-07 | Phenox Gmbh | Vasospasmusbehandlung |
US10456283B2 (en) | 2016-07-13 | 2019-10-29 | Boston Scientific Scimed, Inc. | Apparatus and method for maintaining patency in a vessel adjacent to nearby surgery |
AU2017312421A1 (en) | 2016-08-17 | 2019-03-07 | Neuravi Limited | A clot retrieval system for removing occlusive clot from a blood vessel |
CN109906058B (en) | 2016-09-06 | 2022-06-07 | 尼尔拉维有限公司 | Clot retrieval device for removing an occluded clot from a blood vessel |
WO2018102694A1 (en) | 2016-12-01 | 2018-06-07 | Boston Scientific Scimed, Inc. | Heart valve remodeling device |
US10667838B2 (en) | 2017-01-09 | 2020-06-02 | United States Endoscopy Group, Inc. | Endoscopic snare device |
US10709464B2 (en) | 2017-05-12 | 2020-07-14 | Covidien Lp | Retrieval of material from vessel lumens |
US10722257B2 (en) | 2017-05-12 | 2020-07-28 | Covidien Lp | Retrieval of material from vessel lumens |
US11191555B2 (en) | 2017-05-12 | 2021-12-07 | Covidien Lp | Retrieval of material from vessel lumens |
US11129630B2 (en) | 2017-05-12 | 2021-09-28 | Covidien Lp | Retrieval of material from vessel lumens |
US11298145B2 (en) | 2017-05-12 | 2022-04-12 | Covidien Lp | Retrieval of material from vessel lumens |
EP3638134B1 (en) | 2017-06-12 | 2023-08-16 | Covidien LP | Tools for sheathing treatment devices and associated systems |
US10478322B2 (en) | 2017-06-19 | 2019-11-19 | Covidien Lp | Retractor device for transforming a retrieval device from a deployed position to a delivery position |
US10575864B2 (en) | 2017-06-22 | 2020-03-03 | Covidien Lp | Securing element for resheathing an intravascular device and associated systems and methods |
CN107468391B (en) * | 2017-08-21 | 2023-09-12 | 北京赛铂医药科技有限公司 | Cerebrovascular drawing-line type temporary support |
EP3790502A1 (en) | 2018-05-09 | 2021-03-17 | Boston Scientific Scimed, Inc. | Pedal access embolic filtering sheath |
US10842498B2 (en) | 2018-09-13 | 2020-11-24 | Neuravi Limited | Systems and methods of restoring perfusion to a vessel |
US11406416B2 (en) | 2018-10-02 | 2022-08-09 | Neuravi Limited | Joint assembly for vasculature obstruction capture device |
USD904611S1 (en) | 2018-10-10 | 2020-12-08 | Bolder Surgical, Llc | Jaw design for a surgical instrument |
EP4000540B1 (en) | 2019-03-04 | 2024-02-14 | Neuravi Limited | Actuated clot retrieval catheter |
US11529495B2 (en) | 2019-09-11 | 2022-12-20 | Neuravi Limited | Expandable mouth catheter |
US11712231B2 (en) | 2019-10-29 | 2023-08-01 | Neuravi Limited | Proximal locking assembly design for dual stent mechanical thrombectomy device |
US11779364B2 (en) | 2019-11-27 | 2023-10-10 | Neuravi Limited | Actuated expandable mouth thrombectomy catheter |
US11839725B2 (en) | 2019-11-27 | 2023-12-12 | Neuravi Limited | Clot retrieval device with outer sheath and inner catheter |
US11517340B2 (en) | 2019-12-03 | 2022-12-06 | Neuravi Limited | Stentriever devices for removing an occlusive clot from a vessel and methods thereof |
US11944327B2 (en) | 2020-03-05 | 2024-04-02 | Neuravi Limited | Expandable mouth aspirating clot retrieval catheter |
US11633198B2 (en) | 2020-03-05 | 2023-04-25 | Neuravi Limited | Catheter proximal joint |
US11883043B2 (en) | 2020-03-31 | 2024-01-30 | DePuy Synthes Products, Inc. | Catheter funnel extension |
US11759217B2 (en) | 2020-04-07 | 2023-09-19 | Neuravi Limited | Catheter tubular support |
US11871946B2 (en) | 2020-04-17 | 2024-01-16 | Neuravi Limited | Clot retrieval device for removing clot from a blood vessel |
US11730501B2 (en) | 2020-04-17 | 2023-08-22 | Neuravi Limited | Floating clot retrieval device for removing clots from a blood vessel |
US11717308B2 (en) | 2020-04-17 | 2023-08-08 | Neuravi Limited | Clot retrieval device for removing heterogeneous clots from a blood vessel |
US20210370022A1 (en) * | 2020-05-28 | 2021-12-02 | Incept, Llc | Anchoring strain relief member |
US11737771B2 (en) | 2020-06-18 | 2023-08-29 | Neuravi Limited | Dual channel thrombectomy device |
US11937836B2 (en) | 2020-06-22 | 2024-03-26 | Neuravi Limited | Clot retrieval system with expandable clot engaging framework |
US11439418B2 (en) | 2020-06-23 | 2022-09-13 | Neuravi Limited | Clot retrieval device for removing clot from a blood vessel |
US11395669B2 (en) | 2020-06-23 | 2022-07-26 | Neuravi Limited | Clot retrieval device with flexible collapsible frame |
US11864781B2 (en) | 2020-09-23 | 2024-01-09 | Neuravi Limited | Rotating frame thrombectomy device |
US11937837B2 (en) | 2020-12-29 | 2024-03-26 | Neuravi Limited | Fibrin rich / soft clot mechanical thrombectomy device |
US11872354B2 (en) | 2021-02-24 | 2024-01-16 | Neuravi Limited | Flexible catheter shaft frame with seam |
US11937839B2 (en) | 2021-09-28 | 2024-03-26 | Neuravi Limited | Catheter with electrically actuated expandable mouth |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2821048C2 (en) * | 1978-05-13 | 1980-07-17 | Willy Ruesch Gmbh & Co Kg, 7053 Kernen | Medical instrument |
US4629458A (en) * | 1985-02-26 | 1986-12-16 | Cordis Corporation | Reinforcing structure for cardiovascular graft |
FR2580504B1 (en) * | 1985-04-22 | 1987-07-10 | Pieronne Alain | FILTER FOR THE PARTIAL AND AT LEAST PROVISIONAL INTERRUPTION OF A VEIN AND CATHETER CARRYING THE FILTER |
US4650466A (en) * | 1985-11-01 | 1987-03-17 | Angiobrade Partners | Angioplasty device |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
FR2624747A1 (en) * | 1987-12-18 | 1989-06-23 | Delsanti Gerard | REMOVABLE ENDO-ARTERIAL DEVICES FOR REPAIRING ARTERIAL WALL DECOLLEMENTS |
DE9010130U1 (en) * | 1989-07-13 | 1990-09-13 | American Medical Systems, Inc., Minnetonka, Minn., Us | |
US5002560A (en) * | 1989-09-08 | 1991-03-26 | Advanced Cardiovascular Systems, Inc. | Expandable cage catheter with a rotatable guide |
US5180368A (en) * | 1989-09-08 | 1993-01-19 | Advanced Cardiovascular Systems, Inc. | Rapidly exchangeable and expandable cage catheter for repairing damaged blood vessels |
FR2652267B1 (en) * | 1989-09-27 | 1997-12-12 | Prothia Sarl | CATHETER DEVICE AND FILTER FOR CELLAR VEIN. |
US5059166A (en) * | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
-
1991
- 1991-06-14 US US07/715,164 patent/US5449372A/en not_active Expired - Lifetime
-
1992
- 1992-05-13 CA CA002068582A patent/CA2068582A1/en not_active Abandoned
- 1992-06-15 JP JP4197392A patent/JPH05200048A/en active Pending
- 1992-06-15 EP EP92305455A patent/EP0518704A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US5449372A (en) | 1995-09-12 |
EP0518704A1 (en) | 1992-12-16 |
JPH05200048A (en) | 1993-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5449372A (en) | Temporary stent and methods for use and manufacture | |
US5222971A (en) | Temporary stent and methods for use and manufacture | |
EP0257091B1 (en) | An intravascular stent and percutaneous insertion system | |
EP1755485B1 (en) | Method and system for stent retention using an adhesive | |
EP0679373B1 (en) | Intravascular prosthesis with anti-thrombogenic coating | |
US7226473B2 (en) | Treatment of stenotic regions | |
EP1470798B1 (en) | Method for stent retention using an adhesive | |
US7455687B2 (en) | Polymer link hybrid stent | |
EP0843571B1 (en) | Vascular dilatation device | |
US20100249654A1 (en) | Wire guide | |
WO2004105646A2 (en) | Devices and methods for treatment of stenotic regions | |
US20080027411A1 (en) | Guidewire placement device | |
EP1265651B1 (en) | Selective radiopaque plating of a stent | |
US20060079951A1 (en) | Guide catheter with attached stent delivery system | |
US20220031488A1 (en) | Intracranial stent for insertion into the cerebral venous sinus system and methods of use | |
CA1274740A (en) | Intravascular stent and percutaneous catheter system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |